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ABSTRACT 
The potential of several new sugar matrices as direct compression 
vehicles has been investigated using a systematically organized series 
of tests. These matrices, produced by California and Hawaiian Sugar 
Company (C & H), were evaluated in a comparative manner with two com-
mercially available products (DiPac and NuTab). In some cases, Emdex 
(another commercially available product) was also used. Moisture content, 
density, and flow properties were studied. Scanning electron micrographs 
were obtained t o determine the morphology of the particles . Particles size 
spectra were generated for all the matrices. For some of the C & H Pro-
ducts (AI, B, and C), a computer-interfaced instrumented tablet press 
was used to generate compression profiles from which the compressibility 
of the materials was assessed. 
The formulation efficiency of four C & H Products (AI, AII, B, and 
Brown), DiPac, and NuTab was determined by incorporating the matrices in 
several chewable formulations (ascorbic acid, multivitamin, dextro-
methorphan, antihistamine, antidiarrhea, and antacid) and one non-chewable 
formulation (pediatric strength aspirin). A computer-interfaced tablet 
press, from which compression peak heights were obtained, was used to pr~­
pare the ascorbic acid, multivitamin, and aspirin tablets . The results 
show that the c· & H matrices, particularly Product B, have considerable 
potential as direct compression vehicles. It was also demonstrated that 
the utility of sugar matrices is not limited to the formulation of chew-
able tablets. Further, the results indicate that although matrices maybe 
chemically alike, differences in their physical properties may indeed 
produce gubstantial differences in their intrinsic properties and overall 
formulation hehavior. 
The effect of aging on in- vitro performance of the antacid tablets 
was evaluated. It was found that samples stored under relatively mild 
stress conditions (30°C with 80% relative humidity) for three months had 
reduced acid neutralization rates. It was also found that these storage 
conditions were sufficient to induce substantial aging in sugar coated 
and enteric coated tablets (chlorpromazine and aspirin respectively) ove r 
a four week period. 
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PLAN OF THE THESIS 
This manuscript is divided into seven sections, numbered in Roman 
numerals. The sections are : I. Introduction, II . Experimental, 
III. Results and Discussion, IV. Conclusions, V. References, 
VII . Bibliography, VI . Appendix . The tables and figures are numbered 
in Roman and Arabic numerals respectively. 
In this investigation, several new direct compression matrices pro-
duced by California and Hawaiian Sugar Company were evaluated. These ma-
trices are refered to as C & H AI, All, B, C, or Brown. The Roman numeral 
next to a letter code indicates that the product is prepared by the same 
process as the other product bearing the same letter code; only differing 
in the physical characteristics. The commercially available direct com-
pression sugars studied are: DiPac, NuTab, and Emdex. These are trade 
names of Amstar Corporation, Ingredient Technology Corporation , and Edward 
Mendell Company respectively. 
In some instances, the figures in this manuscript depict plots of the 
relationship between two parameters for up to six matrices . Therefore, for 
purposes of visual clearity, both solid and dotted lines have been used. 
The dotted lines do not differ in any manner from the solid lines . In 
both cases, no mathematical or empirical relationships are implied; the 
lines are the result of the joining of the data points . 
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I. INTRODUCTION 
It is well recognized that the compressed tablet is the most widely 
used pharmaceutical dosage form in North America and Western Europe. 
Defined by the USP as "a solid dosage form containing medicinal substances 
with or without suitable diluent", tablets may be classified either as 
molded or compressed depending on the method of manufacture (1). 
The formulation of tablets has undergone rapid change and development 
over the last several decades. With the emergency of precompression in-
duced die feeding, high speed (and most recently, ultra-high speed) 
computer controlled presses, the manufacture of tablets has become one of 
the most sophisticated aspects of pharmaceutical production. In addition 
to technological advances, recent government regulations regarding the 
bioavailability and efficacy of pharmaceutical products have also played 
a major role in the advancement of tablet production. 
Tablet design and formulation as it exists today can be thought of 
as "the process whereby the formulator ensures that the correct amount 
of the drug, in the right form, is delivered at or over the proper time 
at the proper rate and in the desired location, while having its chemical 
integrity protected to that point (2) . 
Tablet presses operate at varying speeds, ranging from less than a 
thousand to almost a million tablets per hour. In order to ensure that 
adequate weight uniformity is maintained, it is important, especially on 
high speed presses, that the material to be compressed possess acceptable 
flow characteristics . For smooth operation of the tablet press, the 
granulation or direct compression mix must have good compressibility and 
lubricant properties. Many of the active ingredients and excipients do 
not meet these criteria. and it is therefore necessary to prepare a suit-
2 
able granulation prior to the compression process. Alterna t ivel y , a di-
rect compression technique may be employed provided that the componen ts 
mee t the above mentioned cri t eria. A third method, dry gra nulation , is 
limited to situations where nei the r wet granulation nor direct compress ion 
can be used. 
A. Some aspects of table t manufacture 
1. Methods of manufacture 
a. We t granulation 
In spite of its cos tly nature, requiring intensive l abor , conside r-
able material handling, and costly equipment, wet granulation continues 
to be the most widely used process for tablet manufacture. Although many 
of th e products cu·rrently being formulated by wet granulat ion could be 
made by direct compression, existing government regula tions would define 
s uch changes as major modifications. These modifications would require 
changes in ingredients, or a t least, changes in forms of previously used 
excipients. Hence, the newly fo rmulated products would have to un<lergo 
additional stability, bioavai l ability, safe t y s tudies, and a new sub-
mission to regulatory agencies such as the FDA. 
Addi tionally, wet granulation offers several advantages over di rect 
compression. These advantages include: ease of attainment of acceptables 
content uniformity (particularly with soluble , low dosage drugs) , ability 
to r egulate moisture content of the gr anulation during th e dryin g cycle, 
modification of flow characteristics by controlled particle si ze dis tri-
bution, and good distribution of co lor adclitives. Through proper selection 
of granula tion solution and the binder, the dissolution rate of a hydro-
phobic drug may be improved. 
We t granulation is not without i t s limitations. The primary limitation 
3 
is the high cost associated with the process in terms of labor, time, 
equipment, energy, and space requirements. Other limitations include 
soluble dye migration during the drying cycle, and a high incidence of 
component incompatability as a result of the close contact brought about 
by the use of the granulating solvent . In addition, heat and moisture 
sensitive drugs of ten can not be processed by this method. 
b. Direct compression 
Direct compression is the simplest tablet production method . In this 
process, tablets are compressed directly from powder blends of active in-
gredients and suitable excipients (including, disintegrants, and lubri-
cants). These blends flow uniformly into the die cavities to form the 
compacts. The method offers several advantages over wet granulation. 
First and foremost, the process is economical; a limited number of pro-
cessing steps are involved in direct compression compared to wet granula-
tion. Other manufacturing variables such as the mode of addition of the 
binder, drying time, etc. are limited. In tablets made from direct 
compression the particles do not exist in agglomerate form (granules). 
Hence, upon contact with dissolution medium, a prime particle dissociation 
is affected. This in turn may result in faster dissolution which may in-
deed be the single most important factor controlling product bioavail-
ability (3). Since no moisture is involved in the preparation of the 
blends for direct compression, the tablets made from this process tend to 
be more stable than those produced by wet granulation (4). 
However, direct compression has several disadvantages . Many active 
ingredients have poor flow and compression characteristics. This general-
ly requires that the active ingredient be incorporated into a matrix or 
a mixture of matrices to achieve adequate flow and compressibility. Sev-
4 
eral advances have been made in modifying the particle shape and form of 
some active ingredients and fillers to render them more suitable for 
direct compression processing. Such success has been achieved with 
aspirin, acetaminophen, and several vitamins. However, these modifica-
tions tend to increase the price of the raw material, thus negating the 
cost advantage of direct compression. 
In most cases, the amount of active ingredient(s) that can be incor-
porated into a matrix (dilution potential) is quite limited (usually less 
than 30%). Although this level varies with different active ingredients 
and matrix systems, it is a major limitation when formulating high dosage 
drug products. On the other hand, adequate distribution is sometimes 
difficult to achieve when working with low dosage drugs. Also, because 
of lack of, or low levels of moisture in direct compression blends, de-
velopment of static charges may lead to unblending. This phenomenon can 
also occur as a result of vast differences in particle size or density 
among the components of the blends. The blends are most susceptible to 
unblending particularly in the hopper or feed frame of the tablet press . 
Another limitation of this method is the difficulty of achieving deep and 
uniform color distribution in tablets. 
c. Dry granulation (Precompression or Slugging) 
Dry granulation is the process whereby granules of powder blends are 
obtained without the use of heat or solvent. This method is usually re-
served for those formulations which cannct be processed by either wet 
granulation or direct compression due to technical or economical reasons. 
The process entails the formation of slugs from the active ingredient and 
one or more excipient(s). These slugs are then milled and screened into 
a desired particle size distribution range. The "granules" are then mix-
ed with the remaining components of the formulation to obtain the final 
production blends. 
2. Formulation of chewable tablets 
5 
Chewable tablets do not constitute a major portion of the pharmaceu-
tical dosage forms . However, they offer unique convenience to young 
children and some geriatric patients who find swallowing difficult. Chew-
able tablets also provide a rapid onset of activity, such as in the treat-
ment of hyperacidity conditions. They are also useful as target oriented 
dosage forms for the treatment of mouth or throat conditions. 
In the production of chewable tablets, several formulation factors 
are taken into consideration. These factors include: the amount of ac-
tive substance per tablet, flow characteristics of the production blend, 
compressibility, overall stability of the formulation, and organoleptic 
properties . Among these factors, organoleptic properties of the active 
ingredient(s) is perhaps the most important consideration for some formu-
lations. It is generally accepted that, as the required amount of the 
active substance per tablet gets smaller and less bad-tasting, the task 
of achieving an acceptable formulation becomes easier (5). This is be-
cause of the variety of options available in attaining such a formulation . 
However, formulating an extremely bad- tasting or high dosage drug into 
a chewable table t provides an enormous and difficult task. The final 
formula should be one with good taste, acceptable mouth-feel, bioavail-
ability, stability, and quality. Additionally, the product should be 
prepared from an economical formula to ensure market success. 
In order to achieve a product with the foregoing attributes, several 
formulation techniques and approaches are available. To solve the problem 
of bad mouth- feel or after-taste, the formulator oay choose to micro-
6 
encapsulate the active ingredient(s). This is a method of coating the 
drug particles or liquid droplets with polymeric material, thus masking 
the undesirable taste and forming relatively free flowing microcapsules. 
The particle size of the micro-capsules ranges from 5 to 500 microns. 
The technique of micro-encapsulation is heavily limited by patents. A 
detailed review of the various methods of micro- encapsulation has been 
presented by Luzzi (6). Among the various methods described in the liter-
ature (7, 8), phase separation and coacervation appear to be the most 
suitable for taste masking. The polymers used in coating the core mate-
rial include compounds such as carboxymethylcellulose, cellulose acetate 
phthalate, ethylcellulose, gelatin, polyvinylalcohol, gelatin- acacia, 
shellac, and some waxes. Through the use of coagulable water soluble egg 
albumin, Farhadieh (9) has patented an erythromycin form which is suitable 
fo r chewable tablet formulation. In addition to masking unpleasant 
taste, micro- encapsulation may eliminate or minimize potential incompat-
ibility problems. Such success has been reported by Bakan and Sloan in 
the formulation of aspirin and chlorpheniramine maleate (10). It may be 
noteworthy that upon compression, the microcapsule integrity may be 
partially or completely compromised. This, in combination with the extent 
to which the tablet is chewed, and the length of time the drug remains 
in the mouth may determine the degree of taste- masking. 
Adsorption of an active ingredient (with objectionable mouth-feel) 
onto a substrate capable of maintaining the adsorption while the tablet 
material is in the mouth may be an alternative method of masking undesir-
able taste. In this case, the release of the active ingredient from the 
substrate is pH dependent, and occurs in the stomach or i n the intestinal 
tract. A conmercially available adsorba te is that of dextromethorphan 
adsorbed onto magnesium trisilicate by Roche (11). This product is avail-
able in a micronized powder with an active drug content of 10% (w/w). It 
is possible to form adsorbates from other materials such as Veegum and 
silica gel . This process requires that a drug be dissolved in a solvent, 
mixed with the substrate, and the solvent evaporated leaving drug adsorb-
ed upon the substrate (5). 
Ionic exchange, a method analogous to adsorption, has been used not 
only to mask taste, but also to enhance product stability . In this method, 
a substrate resin (ionic in nature) cationic or anionic, possessing an 
affinity for oppositely charged ions on the drug molecule is used. As 
in adsorption , the ideal complex is one in which the drug-resin complex 
remains intact under the salivary pH conditions, but capable of dissociat-
ing in the intestinal environment. Such a complex involving a cationic 
resin, Amberlite (substrate) and vitamin s12 is commercially available 
from Roche as Stablets (11). As alluded to earlier, this complexation 
also enhances product stability. The resin- bound form of vitamin s 12 is 
more stable in the presence of the acidic vitamin C (a common combination 
in chewable multivitamin tablets). 
The most widely used techniques for taste masking and stability im-
provement are spray congealing and spray coating . In spray congealing, 
particles are suspended in a molten coating material which is then pumped 
into a spray dryer in which cold air is circulated. The droplets congeal 
upon con t act with the cold air and are then collected as free flowing 
particles. On the other hand, spray coating entails the evaporation of 
the solvent from the solution of the coating material. This leaves a film 
of coating material on the particles being coated. These two techniques 
produce spherical particles which are usually better flowing than the 
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original form. Sodium dicloxacillin and tetracycline have been success-
fully spray coated to yield free-flowing products suitable for incorpor-
ation into chewable formulations (12). These products are coated with 
a mixture of ethylcellulose and sparmaceti dissolved in methylene chloride. 
The formation of different salts of derivatives of a drug may be an 
alternative method of circumventing an unpleasant taste. However, this 
approach has legal limitations in that it creates a 11 new11 drug entity . 
Thus, subject to safety, efficacy, and stability testing as required in 
the Investigational New Drug (IND) and New Drug Application (NDA) guide-
lines of the FDA . 
The traditional method of wet granulation also offers an approach of 
masking unpleasant taste in a chewable formulation. A bad tasting drug is 
granulated with or without ex~ipients with the aid of a binding solution. 
This method however, requires higher concentrations of binder material 
(compared to formulation of non- chewable formulations) to ensure adequate 
coating. The conventional binder materials such as povidone, cellulose 
derivatives, polyethylene glycols , gelatin, acacia mucilage, and corn paste 
are used. It is reconnnended that where possible, the drug be granulated 
with a sweet binder, and an intra-granular disintegrant (5). The latter 
ensures that the granules disintegrate in· the gastrointestinal tract 
following mastication. The general limitations of wet granulation dis-
cussed in Section Ia also apply to this method. 
A technique that has been used successfully to counteract the un-
pleasant taste of penicillin. is the use of amino acids and protein hydrol-
ysates (13). Some of the preferred amino acids are: sarcosine, alanine, 
taurine, glutamic acid, and glycine (5). Among these amino acids, glycine 
is probably the most widely used. 
a. Flavoring of chewable tablets 
Since a majority of the chewable tablet formulations, are available 
as over-the-counter products, flavor and appearance can make the differ-
ence between commerical success or failure of a product. 
The trend in the pharmaceutical industry today is shifting from the 
traditional usage of flavors such as mint, wintergreen, clove, eucalyptus, 
lemon, and orange just to render the product palatable. Todays flavoring 
encompasses a variety of attributes such as initial impact, mouth- feel, 
after-effects, and olfactory sensations. These considerations are made 
in an effort to produce a tablet with good taste and not merely to mask a 
bad taste. Some of the technology of pharmaceutical flavoring is borrow-
ed from the food industry where a considerable amount of research work 
has been done (14-16) . The selection of the appropriate flavor in the 
pharmaceutical industry today is a well-researched, and executed process. 
The establishment of flavoring criteria and approach is carefully consid-
ered . A typical, well constructed flavoring plan would be one which 
firstly involves a general evaluation of the active ingredient(s) with 
regard to: basic taste, inherent flavor or aroma, intensity of these 
three properties, mouth-feel, taste test, and overall impression. Should 
taste-masking be necessary, the second step would be the selection of an 
appropriate method (discussed in Section 2). The third step involves 
the selection of the other formulation components (eg., vehicles, lubri-
cants, colors, etc.). 
In order to create a "baseline11 for objective evaluation of the tab-
let formulation, unflavored tablets are prepared. The "baseline" batches 
are then comparatively evaluated against flavored batches. Some general 
guidelines for flavor selection exist for those cases where it is not 
feasable to carry out elaborate trials. By considering the formulation 
( 
10 
under the following categories: therapeutic classification e.g. antacid, 
multivitamin, etc.; active drug, in terms of structure, incompatabilities, 
pH versus stability, taste and mouth-feel evaluation, dose per tablet 
and frequency of administration; intended patient population; and mar-
keting preference, i.e. prescription versus over the counter, a formulator 
can select preliminary flavors with relative ease (17). When the final 
flavor is selected, it is important to establish the optimum level, al-
though concentrations of 0.1 to 3% (w/w) are generally recommended. The 
level of flavors in chewable tablet formulations is especially critical 
since these compounds have been implicated in behavior modifications in 
children (18, 19). 
The incorporation of flavors into formulation mixtures generally 
involves blending of the flavor powder into the final blend, usually jus t 
prior to the addition of the lubricant. If several flavored base-line 
formulations are prepared, taste panels may be used to determine which 
production is finally presented to the market. However, the in- put of 
marketing personnel carmot be over-emphasized. 
As indicated in the discussion above, the aesthetic nature of a 
product may actually make a ~otal difference between commercial suc-
cess or failure of a chewable product. It is therefore important that 
the tablet product contain the most suitable color. Although the same 
general considerations of color usage in regular (swallowed) tablets 
apply to chewable forms, there are significant differences in the crit-
e ria for selection. The choice of color or color combinations should 
be in agreement with the selected flavor. The use of colorants in 
pharmaceutical products has been controlled in the United States since 
the enactment of Food and Drug Act of 1906. In this act, the Depart-
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ment of Agriculture established a· group of "permitted colors". Colors 
from this group may be used in foods, drugs, and cosmetics after cer-
tification by the Food and Drug Administration. The certification ensures 
that the colors meet the required specifications, hence, certified dyes 
and lakes. Various colors may be created through manipulation of the 
original 11 permitted colors" to create new colors. However, these blends 
must be recertified (20). Under the Act, the certified colors are 
classified into three groups; FD&C dyes which may legally be used in 
foods, drugs, and cosmetics; D & C dyes which may legally be used in 
drugs and cosmetics; and external D & C dyes which may legally be used 
only in externally applied drugs and cosmetics. The use status of 
certified colors is regulated by the Food and Drug Administration which 
may make changes whenever necessary. Such changes and current status 
are published in the Federal Register. A comprehensive list of colors 
and their matching flavors has been given by Daruwala (5). 
3. Direct compression excipients 
Due to special flow and compression requirements of direct compres-
sion, only a few matrices are suitable for the process. An extensive 
list of the properties of an ideal direct compression excipient has been 
given by Khan and Rhodes (21). Some of the most widely used direct com-
pression excipients (matrices) include several forms of lactose, starch, 
microcrystalline cellulose, dicalcium phosphate, and sucrose. A detailed 
descrption of each of these matrices is given below. 
a . Lactose 
Available in a spray-dried form, lactose is the earliest and the 
most widely used direct compression matrix. The wide availability of this 
material from several sources makes it an attractive product. Initial 
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results "1th spray-dried lactose were disappointing due to browning (22). 
This reaction is catalyzed by tartrate, citrate, and acetate ions (23). 
Advances in the spray-drying technique have eliminated the extent 
of browning considerably. Spray-dried lactose which has about 5% mois-
ture content has less than satisfactory compressibility. However, studies 
have shown that tablets made from this material are not significantly af-
fected by elevated temperature, high humidity or sunlight (24). The prod-
uct's (lactose) poor compressibility and low dilution potential prompted 
further research for a more versatile form of lactose. "Fast-Flo11 Lactose 
is a product of such efforts. Through process modification which inhibit 
the growth of microcrystals, ~-lactose monohydrate microcrystals are held 
together in spheres. This configuration affords the product excellent 
fluidity, low hygroscopicity, and high compressibility. 
Lactose is also available in an anhydrous form, without the water 
of hydration. Because of the high amounts of fines, this product has 
less than optimum flowability. This form may pick up moisture under 
high humidity conditions resulting in an increase in tablet volume 
of up to 15% (3). 
b. Starch 
In its natural state, starch lacks the compressibility and flowability 
essential for a direct compression matrix. The modification that has 
received considerable industrial acceptance is that of Sta-Rx-1500. This 
is a partially hydrolyzed starch that has better flow properties than 
Starch USP. Although Sta-Rx-1500 can be compressed into tablets (25, 26), 
its major application is as a disintegrant (27). 
c. Microcrystalline cellulose 
This form of cellulose was introduced as a direct compression matrix 
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in the early 1960's following the isolation of cellulose fiber chains . 
Under the trade name Avicel, microcrystalline cellulose is available 
in several grades, differing in particle size and flow characteristics. 
Due to the presence of hydrogen bonding among the product's particles, 
excellent compressibility and high capacity can be achieved . Other 
favorable properties of this product include low bulk density, broad 
particle size range, and low coefficient of friction. Several studies 
concerning the use of microcrystalline cellulose in tableting have 
been reported in the literature (28-39). Khan and Rhodes have shown 
that formulations containing microcrystalline cellulose have pressure 
sensitive disintegration (40). Due to cost considerations, this product 
is seldom used as the sole matrix in a direct compression formulation. 
d. Dicalciwn phosphate 
Dicalcium phosphate dihydrate, an inorganic product, is available in 
an agglomerated form under the trade name Emcompress from Edward Mendell 
Company. Its excellent flow and compressibility make it very suitable 
for use in high speed tablet presses. This product is relatively in-
expensive, and possesses an acceptable degree of physical and chemical 
stability. Studies have shown that the material will lose water of 
hydration at elevated temperatures resulting in surface hardening (22). 
Due to the product's poor solubility in neutral or alkaline media, its 
use in the formulation of low water soluble and alkaline sensitive drugs 
is limited. Accelerated stability studies have shown that this product 
is unstable in formulations containing acidic compounds, ascorbic acid 
and thiamine hydrochloride (41). Khan and Rhodes have investigated the 
effect of compressional force on the disintegration time (42)and dis-
solution efficiency (43) of dicalcium phosphate dihydrate formulations 
containing soluble and insoluble disintegrants. Rhodes and co-workers 
have reported the effect of various stress conditions on the physical 
properties of dicalcium phosphate dihydrate formulations (44). 
e . Sucrose 
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Sucrose in its raw form has poor flow, although it can be compress-
ed into a solid mass. The lack of adequate flow has necessitated modifi-
cations to render the product adaptable to ·tablet production by direct 
compression. The material ' s universal availability and abundance has led 
to recent depression in its world market prices. The depression in s ugar 
prices has in turn led to an intensive effort to find new methods of using 
the product. 
Successful modification of the basic s ucrose crystals is exemplified 
by DiPac and NuTab . These are co-crystallized products consisting of 97% 
sucrose with 3% modified dextrins, and processed sucrose with 4% inv.ert 
sugar; 0.1 to 0.2% corn starch, and magnesium stearate respectively (45, 
46). It may be noteworthy that the process of sugar refining involves 
five basic unit operations, namely centrifugation, filtration, decoloriza-
tion, evaporation , and crystallization . The crystallization unit operation 
is manipulated to result in a new crystal aggregate which has enhanced 
tableting properties. In the formulation of DiPac, the resulting co-
crystallized material contains all of the solids of the original feed 
material. Individual grains of sucrose are agglomerated into microsized 
crystals (3 to 30 microns) with the additive ingredient (starch) being 
primarily located in the interstitial spaces between the sucrose crystals. 
It is thought that the DiPac agglomerate have a 'lacy' porous cluster 
of very small individual syrup coated crystals bonded together at their 
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interface by points of contact. It is this porous nature that provides 
co-crystallized products with their tableting characteristics (47). The 
essential steps involved in the patented process of manufacturing DiPac 
are illustrated in Appendix 1. 
4. The use of Tablet Presses in Powder Characterization 
Instrumented tablet presses have been in use in the pharmaceutical 
industry for about three decades. The use of these instruments in the 
industry represents part of a continuing effort to convert tablet produc-
tion from an emperical state into a systematic, and scientifically 
quantifiable process. Studies of tablet press instrumentation have en-
compassed both basic research, and the physics of tablet production. 
However, those studies involved. with the application of this technology 
in analyzing the compression characteristics of individual ingredients, 
the effect of additives, lubricant effects, total formulation, and scale-
up procedures are of considerable practical value (50- 57). 
In order to understand how instrumented tablet presses can be of 
value to a pharmaceutical researcher, an understanding of the process of 
manufacturing tablets by compaction is essential. The production of tab-
lets involves the compaction of a powder system with an external force. 
The powder is contained, and confined within the die cavity and the 
force is applied through the punches (upper and lower). The compression 
of the powder by the punches consolidates the powder material while dis-
placing air from the void spaces. When force is applied to the powder 
in the die(s), bulk volume decreases through a number of mechanisms. 
These mechanisms include: repackaging of the particles, elastic de-
formation (a reversable process), plastic deformation and or brittle 
fracture (when the elastic limit of the system is exceeded), and further 
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compression. 
The instrumentation of tablet presses is an attempt to measure the 
applied force. A commonly used instrument to determine such a quantity 
is the transducer. The transducers used in tablet presses are those that 
convert force measurements to electrical signals in the form of voltage. 
The two types of force measuring devices currently used are the strain 
gauges and piezoelectric transducers. A strain gauge consists of a coil 
of high resistance wire mounted on a paper backing. This gauge shows a 
change in electrical resistance in direct pr oporation to its change in 
length. Piezoelectric transducers contain quartz crys t als which develop 
electrical charges proportional to the applied force . Strain gauges may 
be bonded to the punches or any other part of the press subject to sim-
ilar changes. During compression , the applied force produces a small 
elastic deformation in the punches . This deformation in turn produces 
a change in the resistance of the strain gauges. 
Piezoelectric transducers are available in many sizes, and may be 
placed in several locations of the tablet press . However, piezoelectric 
transducers offer the advantages of being less sensitive to temperature 
effects, and require no bonding to the tablet press. The major limitation 
of this type of transducers is that the change developed in them (as a 
result of applied force) dissipates over time, and thus· are not useful in 
static measurements. 
The signals produced during the various cycles of the tablet press 
may be recorded by various devices such as oscilloscopes, recording 
oscillographs, and high speed chart recorders. The measurements record-
ed during a given run are compared to some standard or expected patterns, 
and may be used to control a particular phase of the tableting process . 
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Schwartz has described how instrumented tablet press data can be used as 
'finger-prints' of tableting ingredients (53). 
Whether a formulator uses a single punch or rotary instrumented 
tablet press, the data generated allows one to see how variables, such as 
specific surface area, apparent density, porosity. hardness (crushing 
strength), volume, thickness, disintegration time, dissolution, lower-
punch force, ejection force, etc., relate to compressional force. This 
information would indicate the force required to produce acceptable tab-
lets. It would also be valuable in assessing how various tablet proper-
ties vary with different pressure levels, reproducibility of the process 
in use, materials' batch to batch variability and scale-up. 
In order to facilitate rapid data collection on a large number of 
tablets, and to determine various compression profile parameters, in-
strumented tablet presses are interfaced with computers. The vast amount 
of data collected enables the generation of the entire compression profile. 
Such profiles can provide a useful tool for trouble-shooting work. 
Although a considerable amount of data has been generated with the 
use of instrumented tablet presses, there is no apparent uniform approach 
in its interpretation. Krycer and Pope (59) have demonstrated the exis-
tence of many discrepancies in the literature. These authors have also 
observed that there are serious conflicts in the conclusions drawn by 
researchers that employ similar methods. Nevertheless, recognizing 
that during tablet compression, the powder particles will und~rgo plas-
tic deformation and/or brittle fracture before a compact is formed, 
the relative proportions of these changes in a formulation may be eval-
uated with the aid of 'Heckel plots' (60). The log of 1 / (1-d), where d 
is the relative density of th2 compact, is plotted as a function of 
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applied pressure . Heckel plots generated for variously sized fractions 
of a given material become superimposed when brittle fracture is the 
major effect,due to the rapid destruction of the original particle size. 
These curves however, remain discrete when plastic deformation is the 
predominant process. The radial force (force transmitted radially to the 
die wall) to applied force profiles are also useful in assessing plastic 
deformation and brittle fracture. Lubricating properties are evaluated 
by measuring the residual force between the die wall and the tablet . 
The generation of applied force versus punch displacement curves enables 
the calculation of the work involved in the tableting process . This 
technique has been applied to evaluate lubricating efficiency (61, 62). 
5. Tablet Coating 
A non-chewable tablet formulation may be coated because of difficulty 
in overcoming unpleasant taste and odor, decomposition of the active in-
gredient (s) due to environmental exposure (particularly for hygroscopic 
formulations, such as those made from sugar matrices), to increase 
aesthetic appearance of the product, or to eliminate undesired effects 
of the active ingredient in the stomach. 
Tablet coating can be divided into four basic categories sugar coat-
ing, film coating (non-enteric and enteric), compression coating, and 
other new concepts (4). The choice of one method over the others will 
depend on specific pharmaceutical or medical considerations. The basic 
processes used in the application of the coating are pan coating, air 
suspension coating , dip coating, and compression coating. Currently, 
pan coating is the most widely used method in industry. Due to technical 
and economical limitations, compression coating and dip coating have not 
gained significant industrial acceptance. 
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a . Sugar coating 
Sugar coating is one of the oldest processes in the pharmaceutical in-
dustry. The technique has remained more of an art than a scientific pro-
cess because of the secretive nature with which it is carried out. 
However, several modifications have been suggested to improve the overall 
process (63). Among the modifications, only pan-spraying technique has 
received considerable acceptance in industry. Some of the significant 
improvements that have been made (over the original process) include: 
atomizing systems t o more evenly distribute coating solutions, lakes of 
dyes to achieve uniform color with minimum color coats, and modern coat-
ing that can more efficiently dry the tablets between coats . The process 
is basically carried out in five stages: (i) sealing- imparts a suffi-
cient degree of water proofing to prevent inward penetration of moisture, 
(ii) sub-coating, achieves rapid build up and rounds of the edges .. 
(iii) smoothing- converts the deficiencies of the subcoating stage (iv) 
coloring-enables product identification and makes the product elegant, 
and (v) polishing-the finishing touch. A comprehensive review of the 
process of sugar coating, and some of its improvements has been made by 
Sutaria (64). 
It is apparent that two factors threaten the utility of sugar coating 
in the pharmaceutical industry. First, the difficulty of automation of 
the process has severely limited its expansion (65, 66). Second, only 
very few skilled individuals are able to perform the technique adequately. 
The stability of sugar coated tablets has been shown to be less than 
satisfactory (67). In some instances, this may be due to cracking of 
the coating as the tablet changes shape with variations in environmental 
conditions, o r when water migrates into the core . However, in some cases, 
the coating may harden considerably (wi thout cracking), thereby im-
peding prompt disintegration of the tablet core. 
b. Film coating 
Film coating is a relatively new technique compared to sugar coat-
ing. The first commercial (non-enteric) film coated product was intro-
duced onto the market in 1954 (2). Film coating may be divided into 
two categories, namely enteric film coating and non-enteric; depending 
on the solubility of the coating material in gas trointestinal fluids. 
The rapid development of this process may be attributed to the 
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vast interest not only in its pharmaceutical application, but also in 
other areas where surface coating is of concern . A number of considera-
tions have been cited as advantages of film coating over sugar coatinG· 
These advantages include the reduction of coating time and material; lack 
of significant increase in tablet weight; no undercoat or water-proof 
coat required; durability and resistance to chipping and c racking; tablet 
can be monogrammed for identification; effective protection to light, 
air, and moisture; lack of adverse effects on disintegration time; non-
aqeous coating solutions can be used; and feasibility of standardization of 
the process and materials. 
Materials such as waxes (68), shellac (69), cellulose derivatives 
(70) and polymeric compounds soluble in, or permeable to gastrointestinal 
juices have been used for film coating. Hydroxypropyl methylcellulose 
(71) methyl hydroxyethylcellulose, ethyl cellulose, hydroxypropyl cellulose, 
povidone (72), sodium carboxymethyl cellulose, and polyethylene glycols 
(73) are the most widely used polymers. 
In contrast to non-enteric film coating, enteric coating has been 
in existence for quite a long time (74). Enteric coating protects acid 
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labile drugs from gastric fluids. It also protects gastric mucosa from 
irritating compounds. Courveur and co- workers (75), and Kanig (76), have 
described an ideal enteric coating material as one that is impermeable 
to gastric juices, susceptible to intestinal juices, non-reactive, 
stable during storage, provides a continuous coating, non-toxic, in-
expensive, and easy to apply with minimum equipment. 
Although the USP XX has disintegration specifications, and USP XXI 
will contain both disintegration and dissolution specifications for enteric 
coated tablets, these products will continue to be troublesome. Studies 
have shown that even for those samples that pass in-vitro tests, success-
ful in-vivo performance can not be assured (75, 78, 79). This variability 
in performance is, at least in part, due to inter. and intra-subject 
gastric and intestinal pH variations. 
Among the vast number of materials that have been evaluated or used 
for enteric coating, the most commonly used products are shellac and its 
cellulose acetate phthalate derivative (78). Studies have shown the 
superiority of cellulose acetate as an enteric coating product (80, 81). 
However, high hygroscopicity, susceptibility to hydrolytic breakdown upon 
storage, and permeability to ionic solutions are the major l imitations 
of this material (76). Other materials that have been successfully used 
recently are: copolymers of maleic anhydride and e thylene compounds (82), 
and ionic polymers synthesized from methacrylic acid and methacrylic 
esters (83) . 
The selection of the solvent for use in film coating as undergone 
dramatic changes in the last decade with more stringent environmental 
regulations through the Environmental Protection Agency (EPA) and Occupa-
tional Safety Haza rd Administration (OSHA). The use of organic solvents 
such as methanol, chloroform, acetone, methylene chloride has been 
significantly reduced (84). The high cost of petroleum products has 
also played a significant role in the reduction of the use of organic 
solvents in film coating. Water-based colloidal coating dispersion sys -
tems, eg. Aquacoat (30% ethyl cellulose pseudolatex) are gaining popu-
larity. 
d. Compression coating 
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This method basically involves the comp r ession of preformed coatings 
onto tablet cores. The technique has been made possible by the develop-
ment of sophisticated compression machinery . However, with the advent 
of film coating, compression coating is rarely employed in the manufacture 
of new drug products. 
B. Evaluation of tablets 
Tablet properties can be divided into two categories: those listed 
in the official compendia, and those widely evaluated by the manufactur-
ers . The official tests include tablet weight variation, assay for 
active ingredient(s), content uniformity, disintegration, and dissolution. 
Descriptions of these tests are available in compendia such as the 
United States Pharmacopiae (1), and the British Pharmacopiae (85). The 
first three official tests listed above ensure that an adequate amount 
of a drug is delivered to the body . Disintegration time and dissolution 
are in-vitro indicators of the in-vivo release patterns of the dosage form. 
These two parameters are often dependent on tablet hardness. In the 
evaluation of antacid tablets, acid neutralizing rates and acid neu-
tralizing capacity (efficiency) are used in place of dissolution rates 
(86-89). Some studies ·have shown a correlation between disintegration 
time and physiological activity (90,91) . However, other studies have 
( 
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shown that such a correlation does not exist (92). In r ecent years more 
emphasis has been placed on dissolution as the better in-vivo performance 
indicator. The correlation between dissolution rate and drug absorp-
tion has been documented (93-95) . Tests such as tablet thickness, 
hardness, friability, and resistance to impact s tress are unofficial. 
Variability in tablet thickness is often indicative of inadequate flow 
c haracteristics of a formulation. The other unofficial tests are in-
dicators of the ability of a formulation to maintain its integrity 
during packaging, shipping, and patient handling. 
B. Accelerated stabili t y testing 
The single major purpose of accelera t ed stability testing is to 
permit one to predict the shelf life of a product at some label storage 
condition, usually "room temperature". While kinetic evaluation of 
stability data may be of value in most dosage forms, this approach is 
limited when applied to tablets . Due to the multip licity of excipients 
in tablet formulations, the use of rate constants through Arrhenius 
equation is impractical. Several approaches have been used to investigate 
the stability of pharmaceutical tablets. Chafetz has sugges t ed the use of 
stability indicating assays (96). Thes~ are procedures which afford the 
selective determination of a drug substance in the presence of its de-
composition and reaction products. Interactions between ingredients in 
a solid dosage form may lead to changes in physical properties such as 
equilibrium solubilities, partition coefficients, and dissolution. Guillory 
and co-workers (97) have suggested control procedures to identify such 
interaction through the use of differential thermal analysis (98). Diffuse 
reflectance has also been shown to be of value in solid- solid interaction 
studies (98) . This technique enables the determination o f chemi- sorption 
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due to surface chelation. 
The literature reveals several publications of an empirical or prac-
tical nature describing incompatabilities, instabilities or other changes 
in the solid state (99-109). In these studies, changes in parameters 
(non-chemical) as a function of time are reported. The moisture sorption 
and volume expansion of tablets made from various forms of lactose has 
been reported by Otuska and co-workers (110) . The moisture sorption and 
tablet expansion was shown to occur more readily with « - lactose leading 
to the formation of the monohydrate. 
The effect of the container on the stability of pharmaceutical pro-
ducts is of considerable importance. Inter-tablet migration, a phe-
nomenon which involves capillary condensation, exemplifies the importance 
of containers in product stability (111). The influence of environmental 
conditions on tablet properties is perhaps the most widely investigated 
area of tablet stability. The effect of light on color stability of 
tablet formulations has been reported (112- 114). Alans and Parrott (115) 
have shown a relationship between the changes occurring in the dissolution 
rate of hydrochlorothiazide tablets at elevated temperature and those 
occurring after prolonged storage at room temperature. The decrease in 
the dissolution rates of sodium salicylate (116), and acetaminophen (94) 
tablets due to aging has been shown. A study on phenylbutazone tablets 
showed a gradual decrease in the dissolution rate with aging (94). 
Other valuable studies on the effect of aging on the physical properties 
of tablets include those of Rhodes and co- workers (117-120), Lachman (121), 
and Sangekar et al (122) . 
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C. Objectives and Significance of the Study 
Although the production of tablets by direct compression has been 
used successfully for a number of years, the understanding of the process 
is still based substantially on empiricism. In particular, little has 
been done to rationalize the use of sugars as direct compression matrices. 
Secondly, little consideration has been given to the effect of cyclic 
environmental changes on the stability of pharmaceutical products. 
The prime objective of this study was to evaluate comparatively the 
potential utility of several oew direct compression sugar matrices . 
Additionally, the effects of cyclic environmental changes on some fund-
amental physical properties of compressed tablets have heen investigated~ 
This study provides a rational approach to tablet formulation 
evaluation and stability analysis . The study is of both theoretical and 
practical importance not only to the pharmaceutical industry, but also to 
the food and chemical industries where packaging of raw materials and 
finished products is of paramount conc~rn. 
II. EXPERIMENTAL 
A. Materials 
1 . Formulation components 
Sodium ascorbate, AG (Lot# 112101) 1 
Ascorbic acid 90% (Lot # 019061) 2 
Microcrystalline cellulose (Lot # 3838-87) 3 
FD & C Yellow# 6 (Lot # AC0693) 4 
Micronized silica gel (Lot # 52003) 5 
Orange flavor (Lot U Ll2281) 6 
Stearic acid (Lot# G19925K08) 7 
Magnesium stearate (Lot II 793404) 8 
Niacinamide (Lot # 548112) 9 
Pyridoxine (Lot# 840031) 10 
Riboflavin (Lot 358030) 11 
~offman La-Roche, Nutley , New Jersey. 
2Hoffman La-Roche, Nutley, New Jersey. 
3FMC Corporation, Newark~ Delaware. 
4
warner Jenkinson, St. Louis, Missouri. 
5
navidson Chemical, Baltimore, Maryland. 
6
warner Jenkinson, St. Louis, Missouri. 
7Ruger Chemical Company, Irvington, New Jersey. 
8Fisher Scientific Company, Fairlawn. New Jersey. 
9Hoffman La-Roche, Nutley, New Jersey. 
lDHoffman La-Roche, Nutley, New Jersey. 
11Hoffman La-Roche, Nutley, New Jersey. 
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Chlorpheniramine maleate (Lot # Dl4539K01) 12 
Phenylp r opranolamine hydrochloride (Lot # Fl4727H31) 13 
Dextromethorphan hydrobromide (Lot # 3011922) 14 
Pseudoephedrine hydrochloride (Lot # Gl950FG10) 15 
Aluminum hydroxide/magnesium carbonate gel (Lot # 16599) 16 
Micronized silica gel (Lot # 78 5004) 17 
Peppermint flavor (Lot # S- 29702) 18 
Calcium carbonate (Lo t # P2352CC) 19 
Pectin (Lot # Fl5852Kl6) 20 
Aluminum hydroxide gel (Lot # Dl8025Cl4) 21 
C&H A, C&H B, C&H C, C&H Brown Sugar (Experimental Lots) 22 
DiPac (Lot # 31E) 23 
NuTab (Lot # T-JD917M) 24 
12Ruger Chemical Company, Irvington, New Jersey. 
13Ruger Chemical Company, Irvington, New Jersey. 
14Hoffman La-Roche, Nutley, New Jersey. 
15Ruger Chemical Company, Irvington, New Jersey. 
16Reheis Chemical Company, Berkeley Heights, New Jersey. 
17
oavidson Chemical Company, Baltimore, Maryland. 
18Food Materials Corporation, Chicago, Illinois. 
19nesmo Chemical Corporation, St. Louis, Missouri. 
20Ruger Chemical Company, Irvington, New Jersey. 
21Ruger Chemical Company, Irvington; New Jersey. 
22california and Hawaiian Sugar Company, Crockett, California. 
23Amstar Corporation, New York, New York. 
24rngredient Techno~ogy Corporation, Pennsauken, New Jersey. 
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B. Equipment 
Engelsmann tapper1 
Ohaus moisture balance2 
Fisher shaker 3 
4 Analog balance 
Strip chart recorder5 
Stainless steel hopper (from Stokes model F press) 6 
Scanning electron microscope 7 
Stokes model F tablet press (single punch) 8 
Computer (Model PDP-11) 9 
Computer - Apple (Model IIE)lO 
Mettler analytical balance (Model H-8, PR1200) 11 
Micrometer 12 
1J . Engelsmann, A.G., Ludwishafen, West Germany. 
2
ohaus Scale Corporation, Florham. New Jersey. 
3Fisher Scientific Company. Fairlawn. New Jersey. 
4Sartorius, West Germany. 
5Linear Instruments Company. Dedham~ Massachusetts . 
6
stokes - Penwalt Company, Warminister, Pennsylvania. 
7
cambridge Instruments, Cambridge . England. 
8
stokes - Penwalt Company . Warminister, Pennsylvania. 
9Digital Computer Company, Marlboro, Massachusetts . 
lOApple Computer Company, Cuperton, California. 
11
zeus Instruments Company , West Germany. 
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( 
Erweka hardness tester (Model NR 19306) 13 
Tarbula Mixer14 
Fitzmill15 
Erweka friabilator16 
USP disintegration apparatus 17 
USP paddle apparatus 18 
Perkin- Ellmer Hitachi spectrophotometer19 
13Erweka Apparatabau, Frankfurt, West Germany 
14Tarbula Instruments, Switzerland 
15w.J. Fitzpatrick Co., Chicago, IL 
16Erweka Apparatabau, Frankfurt, West Germany 
17
vandekamp, Van-kel Industries, Chatham, NJ 
18ttanson Research Corporation, Northridge, CA 
19Hitachi Instruments, Tokyo, Japan 
20
corning Glass Works, Corning , NY 
21Bechman Instruments , Fullerton, CA 
( 
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2. Tablets evaluated in aging study 
The following commercially available tablets were evaluated for the effects 
of aging as descr ibed in part 4 of section C: 
sugar coated chlorpromazine 50 mg~5 
film coated chlorpromazine 50 mg~6 
enteric coated chlorpromazine 325 mg~ 7 
prednisone 10 mg calibrator, 28 
25Lot # 2050T76, Smith, Kline and French, Philadelphia, Pennsylvania. 
X- 43177 , Warner Lambert Company, Ann Abor, Michigan . 
27Lot # 4AE38A, Eli Lilly Company, Indianapolis, Indiana •. 
28
oissolution test performance standard, National Center for Drug Analysis , 
St . Louis, Missouri. 
( 
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C. METHODS 
1. Intrinsic powder properties characterization 
The following intrinsic properties of the matrices were determined: 
bulk and tap densities, moisture content (loss on drying), particle size 
distribution, and flow. Bulk volume was measured by pouring a 50g sample 
of powder into a 100 ml graduated cylinder from a height of approximately 
2.5 cm. Three volume measurements were obtained for each matrix, and 
the values were averaged. Bulk density (gm/ml) was calculated as: 
weight (50g) divided by bulk volume (ml) . Tap density was determined from 
the volume of lOOg samples of powder subjected to a motorized tapping 
device1 for 1000 cycles. Moisture content was determined by heating 
10 gm samples of the bulk powders on an Ohaus moisture balance2. A 
nest of sieves, sizes (U.S. St andard) 20, 40, 60, 100, and 170 , was used 
to measure the particle size distribution. The sieve stack was shaken 
for two minutes an a Fisher shaker 3 . Three replicate runs were per-
formed for each matrix, and the cumulative weight percentage of powder 
at each seive level was calculated . 
Unlubricated samples (one kilogram in size) of each matrix were 
evaluated for intrinsic flow properties by a recording flow meter as 
described by Rhodes.!'.£ al (123), The flow meter consisted uf an 
analog balance4 • a strip chart recorder5 , and a stainless steel hopper6 
suspended over the analog balance. A glass plate was used to close the 
opening of the hopper. The recorder was calibrated such that one kilo-
gram of weight, when placed on the balance (tared with an aluminum pan), 
would cause the recording pen to deflect the entire scale. One kilogram 
of the material to be evaluated was placed in the hopper. When the glass 
plate was removed from the opening of the hopper, the powder fell on 
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the aluminum pan, causing the pen to respond in a manner characteristic 
of the powder system. The recorder was set to the record mode simul-
taneously with the removal of the glass plate. The falling weight was 
recorded as a function of time. The cha rt speed was kept constant at 
30cm/minute. The pen tracings (f low grams) were then analyzed for 
linearity and mass flow (grams/second). The linearity term was cal-
culated from the formula: 
Linearity = (r2 - 0.8) x 100 
where r
2is the coefficient of determination. Three replicate flow g rams 
were determined for each powder system. The values for mass flow and 
linearity were averaged. 
Scanning electron micrographs of the matrices were obtained . The 
bulk powders were sprinkled evenly on adhesive - coated steel stubs. 
The samples were then coated with a 50/50 gold- palladium mixture . The 
coated stubs were placed in an electron microscope 7 and photographed by 
a Polaroid camera (located at the Graduate School of Oceanography, 
University of Rhode Island). 
2. Formulation and evaluation of tablets made from sugar matrices 
Several blends containing a matrix (C&H A, B, C, NuTab, and DiPac) 
and half a percent magnesium stearate were compressed into placebo tab -
lets. An instrumented Stokes model F single punch press 8 , located at 
Merck Sharp and Dohme ' s Research Laboratories, West Point, Pennsylvania, 
was used. The tablet press was instrumented with piezoelectric trans-
ducers and interfaced with a PDP-11 computer9 The software used with 
the compute r enabled rapid collection of data concerning a large number 
of tablets. The computer facilita ted the generation of several com-
pression parameters. ~ transducer in the upper punch holder measured 
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applied force as a function of time . Transmitted and ejection forces 
were measured by a transducer in the lower punch holder. The computer 
generated force/time c urves for applied and transmitted forces by 
receiving signals at a rate of 500 data points per second. In order to 
construct ejection force/time curves, the computer received 2000 data 
points per second. The following parameters were generated for applied 
and transmitted force curves: peak width (seconds, the duration of the 
compression event), center (seconds, time to reach the peak in the com-
pression curve), maximum slope on the ascending curve (the maximum 
positive finite value for the change of force as a function of time, 
Newtons/second), inflection point on the ascending curve (time between 
start of the compression event and the time when positive change in force 
as a function of time is maximal, seconds), inflection point ordinate 
(the value of force, F, at the inflection (Newtons), and area (total 
area under the compression curve, Newtons seconds). A sketch of the 
compression parameters of an applied force curve is shown in Figure 
Since the ejection curve is not as smooth as the compression curve, only 
the peak height was obtained for the ejection force curves . 
Based on data from the above mentioned study , formulation work was 
carried out using the following matriceS: C&H A, B, DiPac, and NuTab . 
A brown matrix manufactured by C&H was also included in this series. 
The formulas used to evaluate the formulation efficiency of the above 
matrices were : aspirin (pediatric), ascorbic acid, multivitamin (con-
taining niacinamide, riboflavin, pyridoxine, and ascorbic acid), and 
antihistamine. The formulation mixtures were compressed into tablets 
by the use of an instrumented Stokes model F single punch press located 
at E. R. Squibb Institute for Medical Research, New Brunswick~ New Jersey. 
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The tablet press was instrumented with two piezoelectric transducers 
(one for each punch holder, upper and lower) and interfaced with an 
Apple IIElO The software to this computer enabled the calculation of 
peak height (compression curve) by picking signals off the press at a 
rate of 200 data points per second. A mean of peak height from data 
on ten tablets was calculated. Since the lower transducer was non-
functional, no ejection force parameters were measured. In addition to 
the tablets made on the instrumented tablet presses, antacid , antitussive, 
and antidiarrhea tablets were prepared on a non- instrumented single 
punch press (located at the research laborato~ies of the Department 
of Pharmacetuics, U.R.I.) similar to the instrumented ones. The formulas 
used are shown in detail in Tables I to VII. 
The following tablet properties we re measured : weight, thickness, 
diameter, hardness, disintegration time, and friability . Dissolution 
profiles were obtained for selected samples of the aspirin formulations. 
Tablet weight was determined by the use of a Mettler analytical balance11 . 
A micrometer12 was used to measure both thickness and diameter. Hardness 
was measured by the use of an Erweka hardness tester 13 . Twenty tablets 
were analyzed for weight, thickness, diameter, and hardness. Friability 
was determined by rotating twenty preweighed (collectively) tablets in 
an Erweka friabilator 16 for four minutes. The disintegration time was 
determined on six tablets with a USP apparatus 17 (Figure 2 ), with 
discs, in distilled water at 37°C. The dissolution profiles of the 
aspirin samples were determined by the use of the USP paddle apparatus18 
with 900ml of one-tenth normal hydrochloric acid at 37°C as the dis-
solution medium. The absorbance of the dissolution samples was 
determined at 26Snm on a Perkin-Ellmer Hitachi spectrophotometer 19 
TAllLE I 
Ascorbic Acid Formula 
Ingredient 
Sodium ascorbate AG1 
Ascorbic acid 90% 2 
Microcrystalline cellulose3 
FD&C Yellow #6 4 
Micronized silica gel5 
Orange flavor6 
Stearic acid7 
Magnesium stearate 8 
Matrix 
Quantity per tablet (mg) 
199.0 
95.0 
20.0 
1.0 
4.0 
7.4 
40.0 
2.5 
631.1 
1000.0 
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Sodium ascorbate, color lake, and silica gel were mixed in a Tarbula 
mixer14 for three minutes. The mix was then passed through a Fitzmill15 
using #0 screen, hammer forward, at medium speed. 
To the above premix, ascorbic acid, flavor, microcrystalline cellulose, 
and matrix were added. The ingredients were blended for five minutes, 
and passed through the Fitzmill with #1 plate. 
The lubricants were incorporated into a small portion of the above premix, 
and passed through a #20 mesh screen, and added to the remainder of the 
premix. The blend was then mixed for ten minutes and compressed using 
~ in . standard concave tooling. 
Ingredient 
Ascorbic acid 90% 2 
Niacinamide9 
Pyridoxine 10 
Riboflavin11 
FD&C Yellow 06 4 
Flavor (orange) 6 
Magnesium stearate8 
Matrix 
TABLE II 
Multivitamin Formula 
Quantity per tablet (mg) 
70.0 
24.5 
3.5 
2 . 5 
2.0 
3. 5 
l. 8 
242.2 
350 . 0 
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Ascorbic acid, niacinamide, pyridoxine. and riboflavin were mixed for 
five minutes using a Turbula mixer. The color lake, flavor, and matrix 
were added to the premix, and screened through #1 plate on the Fitzmill. 
Magnesium stearate was then incorporated into the three above mix and 
blended for five minutes. Standard concave 11/32 in. tooling was used. 
Ingredient 
Aspirin (90%) 
Starch 
Talc 
Stearic acid 7 
Matrix 
TABLE III 
Pediatric Aspirin Formula 
Quantity per tablet (mg) 
88.8 
10.6 
8.0 
0.4 
142.2 
250 .0 
Aspirin was added to the matrix, and blended for five minutes. Starch 
and talc were added to the premix and mixed for five minutes . 
Stearic acid was added to the above blend and mixed for five minutes. 
Compression was carried out using 11/32 in. standard concave tooling. 
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( TABLE IV 
Antihistamine Formula 
Ingredient 
Chlorpheniramine maleate12 
Phenylpropranolamiue Hcl 13 
Aspirin 
Starch 
Talc 
FD&C Yellow 116 4 
Flavor (orange) 6 
Stearic acid 7 
Matrix 
Quantity per tablet (mg) 
1.0 
6. 2 
80.0 
10.0 
8.0 
0.8 
2.0 
4 . 0 
88.0 
200.0 
Chlorpheniramine maleate, phenylpropranolam.ine, aspirin, color lake, 
and matrix were blended for five minutes and screened through the Fitz -
mill using a Ill plate. 
Starch, talc, and flavor were added to the above premix and blended for 
five minutes. 
Stearic acid was added, and the blend mixed for five minutes. Tablets 
were compressed using 11/32 in.standard concave tooling. 
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TABLE V 
Antitussive Formula 
Ingredient 
Dextromethorphan hydrobromide14 
Pseudoephedrine hydrochloride15 
Chlorpheniramine maleate12 
Aspirin 
FD&C Yellow U6 4 
Flavor (o range) 6 
Stearic acid7 
Matrix 
Quantity per tablet (mg) 
7.5 
15.0 
1.0 
325.0 
2. 0 
4.0 
10.0 
135 . 5 
500.0 
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Dextromethorphan, pseudoephedrine, chlorpheniramine, color lake, and 
flavo r were added to the matrix and mixed for five minutes. The mixture 
was screened through #1 plate on the Fitzmill . 
Stearic acid was added to the above blend and mixed for five minutes. 
The tablets were compressed at 4 to 7 kg, using 3/4 inch standard 
concave t ooling . 
TABLE VI 
Antacid Formula 
Ingredient 
Aluminum hydroxide/magnesium carbonate16 
Micronized silica ge117 
Mint flavor18 
Magnesium stearate8 
Matrix 
Quantity per tablet (mg) 
400.0 
50.0 
20.0 
16.0 
1000.0 
1486.0 -
Aluminum hydroxide/magnesium carbonate, and silica gel were added to 
the matrix and mixed for five minutes. The flavor was added to the 
above mixture and blended for five minutes. 
Magnesium stearate was added to the premix, and blended for five 
minutes . 
Tablets were compressed at 4-7 kg, using 3/4 inch standard concave 
tooling. 
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TABLE VII 
Antidiarrhea Formula 
Ingredient Quantity per tablet (mg) 
Calcium carbonate19 
Pectin20 
Aluminum hydroxide 21 
Peppermint flavor19 
Magnesium stearate8 
* Matrix 
*Matrices: 
C&H Product A22 , C&H Product s22 , C&H Product c22 , 
C&H Brown Matrix22 , DiPac23 , NuTab 24 
350.0 
32.0 
65.0 
5.0 
2.5 
1045.5 
1500 . 0 
Calcium carbonate, pectin, and aluminum hydroxide were added to the 
matrix and mixed for five minutes. The flavor was added to the premix 
and blended for five minutes. 
Magnesium stearate was incorporated into the above mixture and blended 
for five minutes. 
Compression was carried out at 4 to 7 kg, using 3/4 inch standard 
tooling. 
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FIGURE 2 
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3. Evaluation acid neutralizing efficiency 
Three matrices, C&H A, B, and Emdex, were formulated into antacid 
tablets . Three tablets from each batch were tested (individually) 
for "acid neutralizing efficiency 11 • The apparatus used consisted of 
a pH meter which was electronically connected to a strip chart recorder5 . 
The tablet sample to be tested was place in lOOml of one-ten t h normal 
hydrochloric acid (preheated to 37°C) contained in 250ml beaker. The 
beaker was placed on a hot plate/magnetic stirrer20 . The heating level 
was set to mentain the temperature of the hydrochloric acid solution at 
37 + 1°C. A two and half centimeter, Teflon coated, stirring bar was 
used to agitate the tablet at 300 rpm. The pH electrodes (p r estandard-
ized to pH 1) were then lowered into the solution to an optimum level 
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not to interfere with the agitation, and the chart recorder simultaneously 
turned to the recording mode . The chart speed was kept constant at lcm/ 
min .. Thus, the change in the pH of the acid medium was recorded as a 
function of time (pH profiles). Tablet samples were analyzed two days 
after manufacture and at the end of a short term aging study. 
In order to determine the effect of aging on the direct compression 
antacid tablets, samples of the tablets, in amber colored bottles, were 
stored under three conditions: room temperature (approximately 25°C), 
30°0 with 80% relative humidity- cyclic , and 30°0 with 80% relative 
humidity- constant. The samples exposed to the cyclic conditions were 
kept in a desiccator at 80% relative humidity in a 30°c oven for twelve 
hours. The bottles containing these samples were removed from the des-
iccator at the end of the twelve hours, and kept in room conditions 
for twelve hours. This cycle was repeated daily fo r three months. 
Those samples exposed to 30°C/80% relative humidity-constant , were kept 
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in the desiccator (within the 30°c oven) throughout the test period . 
At the end of the test period, the tablets were analyzed fo r both physical 
properties and acid neutralizing efficiency. 
4. The effect of aging on the disintegration and dissolution of 
selected coated tablets 
The major limitation of sucrose-based direct comp r ession matrices 
is their high hydroscopicity . The degree of moisture up-take can be 
significantly reduced by coating the tablets . However, little has been 
done to deter mine the adaptability of the various types of coating to 
high temperature and humidity conditions, such as those that prevail in 
tropical regions of the world. Therefore , a study was carried out to 
investigate the effect of short term moderate storage stress on the dis-
integration and dissolution of selected coated tablets . The tablets 
used rep resent each of the main coating processes currently used in in-
dustry . Commercially available samples of sugar coated chlorpromazine25 
(50mg), film coated chlorpromazine (50mg) 26 , and enteric coa ted aspirin 
325mg27 were used. Prednisone lOmg (plain) 28 , a dissolution apparatus 
calibrator, was also evaluated. 
Samples of tablets, twelve to a bottle , were stored in amber safety-
lock~d bottles and exposed to one of the following : 
A - room temperature, approximately 20°C 
B - cyclic (12 hours 30°c , 12 hours room temperature) 
C - 300C isothermal 
D - cyclic (12 hours 30°c with 90% relative humidity, 12 hours 
room temperature) 
E - 30°C isothermal with 90% relative humidity . 
The samples were kept in these conditions for up to four weeks. 
The temperatures were controlled to+ i 0 c and relative humidity was 
controlled to :t 5% . 
At the end of the four week storage period, disintegration times 
were determined for six tablets using the USP method, with discs. Dis-
solution profiles (plots of percent drug dissolves as a function of time) 
were obtained by the use of a six unit USP paddle dissolution apparatus 
in conjunction with an automatic ultra- violet spectrophotometer21 
(located at the Food and Drug Administration's Biopharmaceutics Lab-
oratories, Washington, DC). The A max values for the three drugs: 
chlorpromazine, aspirin, and prednisone were found to be 254, 265, and 
242 nM respectively. The speed of agitation was kept constant, 50 rpm. 
A cell path length of 1 cm was used for chlorpromazine and prednisone, 
and 0 . 1 cm for aspirin. Absorbance values were recorded at a number of 
time intervals for periods of up to sixty minutes . In order to obtain 
the so called tm reading, which represents the total amount of drug in 
each individual tablet, the speed of the paddles was increased from 50 
to 200 rpm and additional samples taken until the rate of change in 
optical absorbance with time became zero. Thus, the dissolution data 
obtained in this study can be expressed in terms of either percent of 
label claim or percent of drug found in each tablet, as indicated by t;;, 
readings. The dissolution media used were: one-tenth normal hydrochloric 
acid (900ml) for both sugar coated chlorpromazine and film coated 
chlorpromazine, and dearated water (500ml) for prednisone. Two differ-
eat media were used for enteric coated aspirin, 900ml of O.lN HCl during 
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the first hour of each dissolution run, and then 900ml of pH 7.4 phosphate 
buffer. The dissolution data was plotted in the form of percent drug 
dissolved as a function of time; mean and standard deviations were 
determined at each sampling time . 
RESULTS AND DISCUSSION 
A. Characterization of direct compression sugars 
1. Intrinsic properties of bulk powders 
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Moisture content, measured as loss on drying, of a direct compres-
sion vehicle is an extremely important property. Formulation variables 
such a lubrication, and compressibility may indeed depend on moisture 
content. It is particularly important that the moisture content of a 
sugar based matrix be carefully regulated as these systems may pick up 
additional moisture from the environment dur ing storage. Table VIII lists 
the moisture content of the matrices investigated. All the matrices had 
moisture levels that were within what is generally regarded as the 
optimum range, 0.75 - 2% (2). 
Density, both bulk and tap, is another major intrinsic property of a 
direct compression matrix. This property contributes substantially to 
the overall flow characteristics of given system. Table IX lists both bulk 
and tap densities for the material studies. Apparent differences in den-
sities were observed between C & H AI and C & H All although these were 
identical products (in the process of manufacture). The products were 
manufactured by the same method with all processes being similar , includ-
ing final sieving. It is thought that since this particular matrix is 
processed in such a manner as to attain a soft texture. more like a pop-
corn, fracture of the particles may occur during packaging. Thus, lot 
to lot, or within lot variability may occur. However, C & H B, a more com-
pact material did not show any significant lot to lot variation in 
particle density. 
Among the intrinsic properties of an uncompressed powder system, 
particle size distribution is perhaps the most important. For many 
Matrix 
c & HAI 
c & H All 
c & H B 
c & H Brown 
DiPac 
Nu1:ab 
TABLE VIII 
Moisture Content of Matrices 
* Moisture content (%) 
0.3 
0 .3 
0.5 
1.0 
0.3 
0.4 
*Loss on drying (n 3) 
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TABLE IX 
Powder Density 
Matrix Bulk Density (gm/ml) Tap 
c & H AI 0.561 0.689 
c & H AII 0.476 0.613 
c & H B 0.674 0. 784 
c & H Brown 0.553 0.654 
Di Pac 0.665 0.806 
NuTab o. 728 0.828 
* Material was tapped for 1000 cycles on a motorized tapper. 
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sys t ems, such as was observed here, a change i n particle size spectra 
will result in changes in density , flow characteristics, and compress-
ibility. Figure 3 is a plot of the particle s ize distribution for the 
matrices studied. The percentage (weight) of powder accumulating at the 
specified sieve aperture was plo t ted on a probability graph. This 
approach yields a linear plot compared to the sigmoidal curves that would 
result from the plot of cummulative amounts versus aperture size on linear-
linear scale . Figure 4 shows the particle size dist r ibution for the two 
batches of C & HA (I and II) . C & HAI showed a mean particle size 
(corresponding to 50% point on the ordinate) of 250µm, whereas C & H All 
had a mean particle size of 150µm. This difference in particle size distri-
bution may account for differences observed in both flow and compressibility 
of the two matrices. 
As has been alluded to, particle size distribution of a direct compres-
sion system is of profound importance. This is exemplified when the flow 
data obtained in this study are examined (Table X). C & HAI with a mean 
particle size of 250µm had a flow rate of 170 gm/sec, whereas C & H All, 
with a mean particle size of 150µm, had a flow rate of only 75 . 7 gm/sec. 
In addition to intrinsic flow properties (unlubricated matrices 
alone), formulation mixtures as outlined in Tables I through VII were also 
studied in a similar manner. A recording powder flowmeter was used in 
both cases. This enabled the determination of mass flow, gm/sec (flow rate) 
i . e. how fast the material could flow, and linearity of the flow (the even-
ness of the flow). The latter, although equally important, is to a degree 
dependent on the configuration of the hopper used. It is generally r e-
garded that for an adequa te flow, a matrix should exhibit a mass flow value 
of 75 gm/ sec and a linearity value no t l es s than 15. In t ables XI and XII 
Matrix 
C & H AI 
C & H All 
C & H B 
C & H Brown 
Di Pac 
2Linearity 
TABLE X 
Intrinsic Flow Properties 
Mean 1 
Mass flow (gm/sec) 
180.8 
75.7 
231.4 
48.5 
161.9 
(r2 - 0.8) x 100 
Mean2 
Linearity 
19 .5 
17.4 
19.6 
18.6 
18.7 
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FIGURE 4 
PROBABILITY PLOT FOR PARTICLE SIZE OF TWO SAMPLES OF C&H A 
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C & H B shows the best overall flow characteristics. 
In direct compression, the capacity, i . e. the amount of an active 
ingredient that can be incorporated into a matrix, without causing signif-
icant formulation problems, is of considerable importance. One of the 
properties of a formulation or powder system that may change with increase 
in percent active, is the flow behavior. Figure S shows the effect of 
increasing levels of ascorbic acid on the flow behavior of the matrices . 
When ascorbic acid was incorporated at twenty five percent level, the 
flow rate of C & H B remained unchanged, whereas that of C & H AI and 
uiPac decreased significantly. Further increase of the levels of 
ascorbic acid to thirty five percent produced decreases in the flow 
rate for all the three products studied. (C & HAI, C & H B, and DiPac). 
However, an increase over thirty-five percent did not produce further 
reduction in flow rate. It may be noteworthy that these levels were 
chosen arbitarily around thirty percent (regarded as the average 
capacity of most direct compression vehicles) . Nevertheless, this level 
may be different with different active ingredients. 
2. Morphology of bulk powders 
Samples of the matrices were photographed using a scanning electron 
microscope. Figures 6 to 11 show the micrographs of the matrices at 
approximately the same magnification. It can be discerned that the 
particles of NuTab and Emdex are almost spherical, with relatively smooth 
edges. The particles of C & H AI (A) appear to be the smallest among 
the group. Although there appears to be considerable similarity between 
the particles of D-".J>ac and C & H B, the surface of C & H B particles 
show discrete crystals (cubes). It may well be the relatively clean 
surface of this particles that affords the product its excellent com-
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TABLE XI 
Flow Properties - Mass Flow (gm/sec) 
Matrix 
Formulation C&HAII C & H B DiPac 
Calcium carbonate/ 56.2 126. 7 85.4 
aluminum hydroxide 
Dextromethorphan HBr 85.6 243. 9 126 . 2 
Chlorpheniramine 
maleate/ 65.5 131. 2 89.8 
phenylpropranolamine Hcl 
Aspirin 49.2 211.0 133.2 
TABLE XII 
* Flow Properties - Linearity 
Matrix 
Formulation C & H AII C & H B 
Calcium carbona t e/ 16.6 16.2 
Aluminum hydroxide 
Dextromethorphan HBr 18.3 19.1 
Chlorpheniramine 
maleate/ 14.1 17.1 
phenylpropranolamine Hcl 
Aspirin 11.2 18.6 
* 
2 Linearity (r - 0 . 8) x 100, n 3 
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FIGURE 6 
SCANNING ELECTRON MICROGRAPH - C&H AI 
l 
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FIGURE 7 
SCANNING ELECf RON MICROGRAPH - C&H B 
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FIGURE 8 
SCANNING ELECTRON MICROGRAPH - C&H C 
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FIGURE 9 
SCANNING ELECTRON MICROGRAPH - DIPAC 
( 
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FIGURE 10 
SCANNING ELECTRON MICROGRAPH - NUTAB 
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FIGURE 11 
SCANNING ELECTRON MICROGRAPH - EMDEX 
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pressibility, while maintaining adequate flow. 
3. Compression parameters and tablet properties 
One of the objectives of this study was to use a computerized, instru-
mented tablet press to screen a series of new direct compression matrices. 
In order to achieve this, the following compression curve parameters were 
generated: height (peak), inflection point ordinate, maximum slope, area 
under the curve, center, and width (at mid height). Three of the inves-
tigational matrices, C & H Al, B, and C, were lubricated with one-half 
a percent of magnesium stearate and compressed to obtain the above 
mentioned parameters. Figure 1 shows a typical compression curve. The 
parameters used to define the curve have been illustrated. The tablets 
were compressed at four compressional force levels. Table XIII shows the 
compression curve parameters measured. Maximum slope, inflection point 
ordinate, and area under the curve were found to vary linearly with maximum 
compressipnal force. Area:height (A:H) may be related to the energy ex-
pended during the compaction process. This parameter may also be related 
to the inherent compressibility of a system as shown by Chilamk.urti and 
coworders (123). Since area under the compression curve is related 
to the work done, i• then A:H is a measure of the time required to transmit 
a given amount of energy to a system. Therefore, it is likely that the 
greater the A:H value, the less the inherent compressibility. The three 
products investigated for compression curve parameters (C & H Al, B, and 
C) showed significant differences in the A:H values. i.e. indicating 
differences in compressibility. This was paralled by differences in the 
ease of tablet press operation at the same setting for the three matrices. 
Sys tems with high Smax:H values have the capacity to accept energy, 
i.e. have work done on them, at a greater rate than those with low 
TABLE XIII 
Compression curve parameters for l ubrica t ed matrices 
Matrix A:H Value, Sec x 103 Intercept, N. 
A 54.93 -0.086 
B 59 .04 - 0.2065 
c 61.34 -0 .2466 
lPO:H Value (xl0 2) I ntercept, N 
A 57 .34 0 . 2479 
B 54.53 0 . 5057 
c 55.03 o. 4724 
S :H Value, Sec -1 Intercept, N. Max 
A 23. 79 16. 77 
B 23.46 57 .13 
c 22 . 22 75.61 
A:H - Area:Height 
lPO:H - inflection point· ordinate:height 
SMax:H - Maximum s l ope:height 
R2 - correlation coefficient 
Sec 
Sec - 1 
65 
R2 (Number of 
Poin t s) 
0 . 99 (4) 
0.99 (4) 
0 . 99 (4) 
R2 (Number of 
Points) 
0 . 99 (4) 
0 . 99 (4) 
0.99 (4) 
R2 (Number of 
Points) 
0.99 (4) 
0.99 (4) 
0.99 (4) 
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Smax: H values. The three varieties of C & H products did not show 
significant difference in Smax:H values (Table XIII). Chilamkurti (123) 
has also shown that there was no significant difference in this parameter 
for two types of dicalcium phosphate dihydrate. It is conceivable that 
this parameter is inherent of the chemical properties of a system. 
Inflection point ordinate, slope (maximum), and area under the curve 
varied linearly with applied force, Figures 12, 13, and 14 respectively. 
Disintegration time appeared to be independent of tablet hardness (Figure 
15), probably due to the fact that these water soluble matrices form 
tablets which undergo erosion as opposed to disintegration ~ ~-
This phenomenon of erosion has been compared to the peeling of an onion, 
one layer at a time. 
Physical properties of the tablets made from the lubricated matrices 
(C & H AI, B, and C) are shown in Tables XIV-XVI. As expected from sat-
isfactory flow data, weight uniformity for all the three matrices was 
excellent. Tablet thickness decreased with increase in applied force. 
Both C & H AI and C & H B showed increases in friability when tableted 
at high compressional forced (Table XV). This increase in friability was 
observed although hardness appeared to have increased with higher com-
pressional forces . 
Figures 16 and 17 show the effect of compressional force on the 
hardness of tablets made from lubricated matrices (C & HAI, B, and C). 
The hardness values used in Figure 16 were obtained immediately after 
compression, while those hardness values used in Figure 17 were obtained 
forty five days after manufacture. There appears to be an aging process 
in which a reduction in tablet harndess occurs. 
All the matrices investigated except the Brown sugar,. were incorpo-
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( TABLE XIV 
Tablet Proper t ies fo r Lub r ica t ed Matrices 
Ma t rix Compressional Fo rce Weight (mg) Thickness (mm) 
Replicat e (Newtons x 10-3) Means R.S.D. Mean R.S.D. 
c & H AI 
1 7.2 292. 4 0 . 71 3.27 0 . 34 
2 13.8 329.5 0 . 78 3. 34 0.48 
22. 3 300 . 7 0.54 2. 87 0 . 27 
4 26 . 3 294 . 1 0 . 30 2 . 77 0 . 45 
c & H B 
1 12.2 303.1 0.45 3.07 0 . 29 
2 19 .6 301. 7 0.59 2.91 0.48 
3 26.1 298.1 0.62 2. 80 0 . 47 
4 31. 5 298 . 7 0.87 2. 76 0 .53 
c & H C 
1 13.5 302 . 3 0.44 3.04 0.27 
2 17.6 305.2 0.37 2. 98 0.55 
3 25.1 299 . 3 0.63 2 . 83 0 . 36 
4 31.9 298 . 8 1. 27 2. 76 0.88 
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TABLE x:v 
Tablet Properties for Lubricated Matrices 
Matrix Compressional Force Hardness (Kg) Friability 
Replicate (Newtons x 10- 3) Mean R.S . D. Per cent 
c & H AI 
1 7.2 0 . 90 14.34 1. 47 
13 . 8 3.75 6. 29 1.58 
3 22.3 6 . 43 13.36 2.16 
4 26.3 9.78 18.84 2. 67 
c & H B 
1 12.2 2.26 9 .49 1.93 
2 19 .6 4.56 7.75 1. 69 
26.1 8.67 7. 24 2. 64 
4 31.5 9 . 36 9 . 95 2.46 
c & H C 
1 13.5 4.46 4 . 89 2.97 
2 17.6 6.28 9.39 2. 98 
3 25.1 7.62 9.88 2. 88 
4 31.9 10 . 82 6.34 2.60 
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TABLE XVI 
Dis i ntegra t ion Time for Placebo Tablets 
Matrix Compressional Fo r ce Disint egra t ion time (Min ) 
Replicate (Newtons x 10-3) Mean Range 
c & H Al 
1 7. 2 3. 14 2.83 - 3.50 
2 13. 8 4.86 4.50 - 5 . 50 
3 22 . 3 4.36 3. 75 - 4. 58 
4 26 . 3 4. 10 3.67 - 4. 75 
c & H B 
12.2 4.53 4 .17 - 5 . 17 
19.6 4.31 4 . 16 - 4.50 
26.1 4.25 3 . 75 - 4.58 
4 31. 5 4.14 3.67 - 5.00 
c & H C 
1 13 . 5 4.68 4.00 - 5 . 67 
2 17.6 4 . 50 4.16 - 4 . 83 
3 25.1 4.30 4.08 - 4. 67 
4 31.9 4. 19 3. 67 - 4.75 
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rated into a pediatric aspirin formulation . The aspirin used was a 10% 
starch granulated type for direct compression. This type of aspirin was 
chosen over the crystalline material to enable the study of the formula-
tion variables, such as compressional forces, on the release of an active 
ingredient from a sugar matrix (water soluble) where tablet disintegra-
tion occurs through a combination of matrix erosion, and actual particle 
disintegration (starch-aspirin granules). Table XVII and XVIII show the 
physical properties of the aspirin tablets made at different compressional 
forces . Figure 18 represents the effect of compressional forces on tab-
let hardness. It was observed that C & H AI produced the hardest tablets 
at all compressional forces . 
Figure 19 illustrates the effect of compressional force on tablet 
thickness. As expected, there is an initial decrease in thickness with in-
crease in compressional force; the upper punch traveling much deeper into 
the die cavity with the adjustment on the pressure setting to compress the 
tablet harder. At compressional forces greater than ten thousand Newtons, 
no change in tablets thickness is produced with increase in compressional 
force. At such compaction levels is conceivable that a maj ority of the 
void spaces have been occupied by particles . Further compaction produces 
particle interaction with no appreciable change in the overall volume 
~ ilie ~blH. 
Figure 20 is a plot of the effect of compressional force on the 
friability of the aspirin tablets. C & H B and DiPac, two of the matrices 
that showed some similarity in morphology, particle size distribtuion and 
density, showed identical, almost superimpossible, profiles. C & H AI 
and AII had similar profiles. However, the profile observed for those 
tablets made from NuTab was very different. The tablets showed higher 
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TABLE XVII 
Physical Properties for Aspirin Tablets 
Matrix Compressional Force Hardness (Kg) Friability 
Replicate (Newtons x 10-3) Mean R.S.D . Percent 
c & H AI 
2.7 0.47 29. 78 1.48 
2 4.1 0.78 38.46 1.00 
3 8.0 2.32 16 . 71 0 . 40 
4 15.5 4.92 9. 75 0.50 
5 17.1 4.95 9. 29 0.40 
c & H All 
2.0 0.70 21. 42 0.80 
2 3.0 3.67 17. 71 0 . 40 
8.0 6.27 7. 97 0.30 
4 10.2 7. 75 10 .96 0 . 30 
5 16.4 7.35 12.92 0 . 30 
c & H 8 
3.0 0. 75 40.00 4.0 
3.8 2.45 20.40 0.40 
3 8.9 3. 70 7.56 0.40 
4 10 . 3 5.08 8. 66 0.30 
5 18.4 6.20 14 . 51 0.40 
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TABLE XVII (Continued) 
Physical Properties for Aspirin Tablets 
Matrix Compressional Force Hardness (Kg) Friability 
Replicate (Newtons x 10- 3) Mean R.S.D. Percent 
DiPac 
1 3.0 0.32 37.50 * 
2 4.7 0. 72 37.50 4.00 
9.0 1. 80 20.00 0 . 80 
4 17 .1 4.32 9 . 02 0.10 
5 19. 8 5 . 07 10.84 0.30 
Nu Tab 
1 3. 0 0.25 
* 
2 5.6 0.38 34. 20 
* 
7.3 0.88 ' 27 . 27 0 .80 
4 16.3 2.07 15.45 0.90 
5 21.3 3. 35 8.65 1. 70 
* 
All Tablets . broke into small pieces 

80 
TABLE XVIII (Continued) 
Physical Properties for Aspirin Tablets 
Matrix Compressional Force Weight (mg) Thickness (mm) 
Replicat e (Newtons x 10-3) Mean R. S.D. Mean R. S. D. 
DiPac 
1 3.0 251.3 0.99 4.34 0 . 46 
4.7 250.9 0.84 4. 19 0.69 
3 9 . 0 253.5 1.00 4.06 0 . 78 
4 17.1 253.2 1.06 3. 93 0 . 90 
5 19.8 251. 9 0.88 3.88 0.75 
NuTab 
1 3.0 255.2 1. 66 4. 21 0 . 64 
2 5.6 259.2 1.18 4.16 0 . 62 
3 7.3 256. 5 1.40 4.06 0 . 62 
4 16.3 256 . 1 0.98 3. 96 0 . 89 
5 21.3 258. 7 1.38 3. 93 1. 05 
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friability when produced at higher compressional forces. 
Figure 21 illustrates the relationship between tablet hardness and 
friability for the aspirin formulation . Similar trends, as those noted in 
friability versus compressional forces were observed. C & H B and Dirac 
showed identical profiles. Likewise, C & HAI and C & H All had identical 
profiles. However, NuTab displayed an increase in friability with increases 
in hardness . 
The effect of compressional force on the disintegration of the aspirin 
tablets is presented in Figure 22. Tablets made with C & H All showed the 
highest overall disintegration time, whereas tablets made from C & H AI 
showed the lowest disintegration times (disintegrated most rapidly) . Those 
tablets made from the other three matrices (C & H B, DiPac, and NuTab) had 
similar disintegration profiles. 
Figure 23 shows the relationship between hardness and disintegration 
for the aspirin formulation. Although it can not be pointed out as to 
which of the two parameters is the independent variable, and which is the 
dependent variable, such a plot allows the visualization of the 
relationship between the two tablet properties . A general trend of an in-
crease in disintegration time with increase in hardness was observed. 
C & H All showed a sharp increase in disintegration time when tablet hard-
ness exceeded five kilograms. Although nothing conclusive can be drawn 
from this particular observation, since C & H All was the only matrix that 
was compressed over five kilogram tablet hardness, it quite conceivable 
that at hardness levels above five kilograms, tablet penetration by water 
is much slower compared to penetration in softer tablets. 
Figures 24 through 28 show dissolution profiles for aspirin tablets 
made a t four different compressional force for each matrix, C & H AI, 
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C & H AII, C & H B, DiPac, and NuTab respectively. 
In order to allow the interpretation of the entire dissolution pro-
files, in relationship to other tablet properties, the concept of "dis-
solution efficiency" was used. Khan and Rhodes have used this concept to 
demonstrate the effect of pressure on the dissolution of some direct com-
pression systems (124). In this approach, the area under the dissolution 
curve at any reference time, t, is divided by the area of a rectangle 
formed by a line drawn perpendicular to 100% drug dissolved point, and 
another line drawn perpendicular to the time axis at a reference time point. 
The ratio of the two areas is then expressed as a percentage, thus, "per-
cent dissolution efficiency" (Figure 29). 
Figure 30 shows the effect of compressional force on the dissolution 
efficiency of the aspirin tablets. A general trend of a decrease in dis-
solution efficiency with increase in compressional force can be observed. 
Figure 31 shows the effect of hardness on the dissolution efficiency 
of aspirin tablets. A general trend of a decrease in dissolution efficiency 
with increase in tablet hardness was evident. During the dissolution stud-
ies it was observed that at the end of a sixty minute interval, there 
were appreciable amounts of intact tablet material left at the bottom 
of the dissolution vessels; as the tablet hardness increased. The mate-
rial at the bottom of the dissolution vessels appeared to be similar to 
the aspirin granules used in the formulation. These 'granules' remained 
intact even when the stirring rate was increased from 50 rpm to 200 rpm, 
in an attempt to obtain the so-called t~ values. In order to overcome 
this problem, a long procelain pestle was used to break up the granules, 
thereby enabling the determination of the total aspirin content of the 
tablets. Therefore, it is apparent that with increase in compressional 
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Tables XIX and XX show the physical pr operties of the ascorbic acid 
tablets made at four different compressional forces . The weigh t and thick-
ness uniformity were excellent, generally below 1% relative standard de-
viation. For all the matrices studied, tablet hardness increased with 
corresponding increase in compressional force . The friability of the tab-
lets decreased with increase in compressional force. In order to facili-
tate visual inspection of the data, the data per taining to the physical 
properties of the ascorbic acid tablets has been presented graphically 
in Figures 33 through 34. 
As would be expected, tablet thickness decreased with increasing com-
pressional force (Figure 32). Figure 33 shows the effect of compressional 
force on the hardness of the tablets. C & H Product Al produced the hard-
est tablets, whereas NuTab produced the softest tablets at approximately 
the same compressional force . All matrices produced tablets that were 
considerably friable at compressional forces below fifteen thousand Newtons 
(Figure 34). 
Tables XXI and XXII show the physical properties of the multivitamin 
tablets. C & H Al and AII showed slightly higher variation in tablet wei ght 
at low compressional forces. However, the relative standard deviation for 
tabiet thickness remained below 1%. Since the weight adjustment was not 
altered when the compression settings were changed, the observation can 
only be explained by variability in the flow rates of the products. The 
hardness of the tablets increased with higher compressional forces . (Table 
.XX.II). However, at compressional forces greater than eighteen thousand 
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TABLE XIX 
Physical Properties for Ascorbic Acid Tab le ts 
Matrix Compressional Force Weight (gm) Thickness (mm) 
Replicate (Newtons x 10-3) Mean R.S.D. Mean R.S.D. 
c & H AI 
4.5 1.012 1. 54 6.60 0.54 
7.4 1.004 1.15 6.32 0.28 
3 12.9 1.005 0.99 5.99 0.48 
4 23.0 1.002 0.99 5. 76 0.48 
c & H All 
6.1 0.939 4.00 6.47 0.67 
2 9.7 0.977 0.80 6.14 0.42 
3 16.1 0.965 1. 45 5.84 0.41 
4 19 .1 0.952 1.15 5.58 1.64 
c & H B 
4.7 0.994 0.66 6.14 0.39 
12.1 0.996 0.94 5.89 0.54 
3 22.8 0.993 0.97 5.53 0.42 
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TABLE XI X (Continued) 
Physical Properties for Ascorbic Acid Tablets 
Matrix Compressional Force Weight (gm) Thic.kness (mm) 
Replicate -3 (Newtons x 10 ) Mean R.S . D. Mean R.S.D. 
c & H Brown 
1 7.4 1.005 0.48 6. 14 0.30 
9 . 0 0.996 0.76 5.96 0.41 
17 . 1 0 . 996 0 .76 5.94 0 . 49 
4 17.4 0.986 0.44 5. 61 0 .31 
DiPac 
1 9 . 1 1.024 0. 78 6.22 0.28 
2 12.1 1.026 0 . 31 5.96 0.44 
3 18.7 1.026 3.41 5.79 0. 77 
NuTab 
1 10 . 3 0.991 0 . 79 5.96 0 . 53 
2 15 . 2 1.004 0.94 5. 79 0 . 63 
3 19.9 0 . 983 0 . 66 5 . 61 0.46 
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TABLE XX 
Physical Properties for Ascorbic Acid Tablets 
Matrix Compressional Force Hardness (Kg) Fri ability 
Replicate -3 (Newtons x 10 ) Mean R.S.D. Percent 
c & H AI 
4.5 1. 27 25.19 9.90 
2 7.4 2.85 15. 78 3.60 
3 12.9 7 .15 12.16 1.18 
4 23.0 11. 80 10. 76 0. 71 
c & H All 
6.1 1.00 35.00 * 
2 9 . 7 4.10 5.85 1.43 
3 16.1 7.50 10.66 0.83 
4 19 .1 10.12 10. 47 0.65 
c & H B 
1 4.7 1. 25 18.40 
* 
2 12.1 3.40 13.82 1. 80 
3 22.8 10.40 9 .13 0.60 
* 
All tablets broke into small pieces 
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TABLE XX (Continued) 
Physical Properties for Ascorbic Acid Tablets 
Matrix Compressional Force Hardness (Kg) Friability 
Replicate (Newtons x 10-3) Mean R.S.D. Percent 
c & H Brown 
l 7. 4 l.15 18.26 11.00 
2 9.90 l.95 27.16 6.20 
3 17.1 4.90 9.18 l. 30 
4 17 . 4 6.67 8.99 0.80 
DiPac 
1 9 . 1 0.95 26 . 31 12.69 
12.1 2.47 11. 74 2.03 
18.7 4.60 21. 73 l.17 
NuTab 
1 10.3 l. 37 19. 70 5 . 25 
15.2 3.10 11.93 1. 80 
3 19.9 4. 75 21. 05 l.04 
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TABLE XXI 
Physical Properties for Multivitamin Tablets 
Matrix Compressional Force Weight (mg) Thickness (mm) 
Replicate (Newtons x 10-3) Mean R.S . D. Mean R.S. D. 
c & H AI 
1 1.6 348.5 8 . 89 5.96 0 . 50 
2· 4.5 353.8 0.76 5 . 53 0.45 
3 7.1 350 . 0 o. 79 5 . 27 0 . 43 
4 12 .0 351.6 1.08 5.10 0.64 
5 22.3 351.5 0 . 71 4. 97 0. 80 
c & H All 
2.6 321. 5 1. 94 5.46 0.65 
5.2 320.0 1.85 5.02 0.46 
3 9.2 323.9 o. 75 4.90 0.65 
4 15.8 327 . 2 o. 60 4.74 0 . 46 
22. 7 328.0 0.56 4. 72 0.68 
c & H B 
3.0 344 . 8 0.32 5.38 o. 74 
2 4.7 348.0 0.53 5.23 0.42 
3 8.3 349.2 0.26 5.08 0 .36 
4 14. 3 349.3 0.23 4 .97 0.41 
5 22.4 351.3 0.44 4.90 0.43 
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TABLE XXI (Continued) 
Physical Properties for Multivitamin Tablets 
Matrix Compressional Force Weight (mg) Thickness (mm) 
Replicate - 3 (Newtons x 10 ) Mean R. S.D. Mean R.S.D. 
c & H Brown 
1 2.5 250 . 2 0 . 11 5 . 48 0.24 
2 5.8 350 . 8 0 . 51 5. 28 0.44 
3 11 . 0 353 . 0 0.38 5 . 02 0.61 
4 18 . 8 353 . 6 0 . 67 4. 92 0.38 
5 24.9 355.3 0.32 4.90 0.38 
DiPac 
1 3. 7 347.0 0 . 42 5 . 28 0 . 50 
9.5 347 . 6 0.24 5.13 0.40 
3 15.2 345.8 0 . 35 4. 97 0.36 
19. 3 346.9 0 .51 4 . 97 0 . 48 
NuTab 
1 4.0 352 . 0 0.51 5.46 0.58 
5. 3 351. 2 0.25 5 . 23 0. 30 
10.4 349.7 0 . 48 5.05 0.42 
4 11.1 351. l 0.31 5.08 0.56 
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TABLE XXII 
Physical Properties for Multivitamin Tablets 
Matrix Compressional Force Hardness (Kg) Friability 
Replicate (Newtons x 10-3) Mean R.S.D. Percent 
c & H AI 
1 1. 6 1. 5 18.98 1.14 
2 4.5 5.3 11.13 0.35 
3 7. 1 8.7 10.34 0 . 28 
4 12 . 0 12.1 14.88 0.21 
5 22.3 10.5 12.38 3. 30 
c & H AII 
1 2.6 3. 0 22 . 66 0.54 
2 5.2 7.2 18 . 05 0 . 55 
3 9.2 9.4 11. 70 0. 30 
4 15.8 13.2 6.05 0.27 
5 22 . 7 10.2 13 . 91 * 
c & H B 
1 3.0 3.0 13. 33 0. 76 
4.7 4.8 10.37 0. 43 
3 8.3 6 . 9 11. 79 0.30 
4 14.3 10.0 5 . 30 0.28 
5 22.4 10.5 10.61 0.31 
* Significant capping was observed 
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TABLE XXII (Continued) 
Physical Properties for Multivitamin Tablets 
Matrix Compressional Force Hardness (Kg) Friability 
Replicate -3 (Newtons x 10 ) Mean R.S . D. Percent 
c & H Brown 
1 2. 5 1. 27 21. 25 2.80 
2 5.8 3.31 12. 72 0.64 
3 11.0 9.10 15.30 0 . 36 
4 18.8 12.10 6.61 0.32 
5 24.9 10.70 13.50 0.35 
DiPac 
1 3. 7 2.00 10.00 2.20 
2 9 . 5 3.85 8. 05 0.60 
15.2 7.10 20.56 0.40 
4 19 . 3 5.00 16 . 00 * 
NuTab 
1 4.0 0.88 19 .31 0.42 
2 5.3 2. 70 11.11 0. 71 
3 10.4 5. 20 14.61 0.45 
4 11. l 5 . 90 14.57 l. 64 
* Significant capping was observed 
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New tons, a decrease in hardness was observed. This corresponded to levels 
of compression where considerable capping was noted. Figures 36 through 
39 represent the data ob tained on the Multivitamin tablets. Figure 37 
shows the effect of compressional force on tablet thickness. As expected, 
tablets thickness decreased with increasing compressional force. A 
special feature with a plot such as one presented in Figure 36 is that it 
enables one to visualize the compressibility of a powder system. Here, 
in a relative manner, it can be observed that at compressional forces 
greater than ten thousand Newtons, C & H All compressed the most, i.e. 
had the greatest decrease in tablet thickness. 
Figure 37 is a representation of the effect of compressional force 
on tablet hardness. It was observed that C & H AI and AII had almost 
identical compressional profiles, producing the hardest tablets, whereas 
DiP~c and NuTab also exhibited similar compressional profiles (producing 
the softest tablets, at all compressional levels). Those tablets from 
C & H Product B and the brown matrix showed similar trends. 
The friability of the multivitamin tablet decreased with increase 
in compressional forces (Figure 38). At compressional levels below ten 
thousand Newtons, there was considerable difference in the fri-
ability of the tablets obtained from various matrices. However, when the 
tablets were compressed at compressional force greater than ten thousand 
New tons, no significant difference was observed among the friability 
values. Figure 39 shows the relationship between hardness and friability 
of the multivitamin tablets. The differences in friability were only 
observed at hardness levels below 4 kg. At levels where optimum hardness 
for most chewable formulations, approximately 7 kg, no significant 
difference in friability was observed. 
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4. Antacid neutralizing efficiency of direct compression antacids 
Antacids are useful in the treatment of acute and chronic upper 
gastrointestinal disorders. Antacid may be formulated as gums, tablets, 
lozenges, powders, or liquids. In most cases the liquids, in form of 
suspensions offer the most prompt relief, particularly in hyperacidity 
conditions. However, these products are bulky and may be inconvenient 
to carry. Tablets, particularly, chewable forms, offer an advantage over 
suspension (especially for pediatric and generiatric groups who find liq-
uids awkward or inconvenient). However~ it has been shown that tablets 
are not equal to liquid antacids on a milligram-for-milligram basis (125) . 
Although both the USP (1) and BP (85) offer in-vitro methods fo r ant-
acid evaluation, a review of the literature shows a varie t y of methods 
used to evaluate these products. In 1974, the Food and Drug Administra-
tion introduced an in-vitro test (86) to determine the antacid-neutraliz-
ing rate and the acid-consuming capacity of over-the- counter an t acid 
products. However, it should recognized that although an in-vitro test 
can app roximate in vivo acid-consuming capacit y, speed and duration of 
activity, and maximum buffering capacity of an antacid, other variable 
such as gastric emptying, changes in the acid secretion rate, interaction 
of antacid with glycoproteins and mucoprotein of the gastric juice, coating 
of the gastric mucosa by antacids, and the effect of antacids on the en-
dogenous control of gastric acid sections can not be accounted for (126, 
127). 
The purpose of this study was to determine the effect of aging on the 
release of an antacid from water soluble direct compression matrices. 
Thus, the study was designed to determine the rate and extent of acid 
neutralization, before and after aging. The various methods for antacid 
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testing available in the literature can be classified into three main 
categories: Static, dynamic, and pH-stat. An example of the Static 
method is that found in the USP XX (1) for the analysis of dried aluminum 
hydroxide gel . The main disadvantage of this method, is that it provides 
a limited picture of the entire acid neutralizing process. The dynamic 
and pH-stat methods provide an approach in following the progress of acid 
neutralization in a continuous manner. The British Pharmacopiae (85) 
offers an example of a dynamic method where the pH of an acid medium is 
measured as a function of time. 
In the analysis of acid neutralizing efficiency of the antacid tab-
lets manufactured in the study, a method similar to the British Pharmaco-
peal guidelines for the analysis of aluminum hydroxide tablets was used. 
This method is simple, and does not require elaborate equipment. Although 
it is recognized that as the tablet matrix erodes within the acid medium 
(intact tablet were used) a suspension- like system forms, and may affect 
the pH readings, the overall effect is negated as similar test conditions 
were used for samples tested before, and those tested after aging. 
Figures 40 to 48 show the acid neutralizing profiles of the tablet 
samples studied. The solid lines show the pH-time tracing (and neutraliz-
ing profiles) for samples test before aging, and the dotted lines show 
profiles for samples subjected to one of the aging conditions (ambient, 
J0°C/80% RH cyclic, or J0°C/80% RH constant). Tablets samples of C & H 
AI obtained from all the three storage conditions showed significant change 
in the acid neutralization profiles (Figures 40, 41, and 42). Only sam-
ples stored at J0°c with 80% relative humidity (constant) showed signif-
icant change in the pH-time profiles fo r C & H B (Figure 45). This trend 
was also observed for the tablets made from Emdex (Figure 48). 
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This study, although conducted over a relatively short period of 
time (three months), was able to detect appreciable change in the release 
of antacid material from the tablet matrix. It is therefore quite 
conceivable that over a prolonged period of time, even at relatively mod-
erate stress conditions, antacid formulated in sugar matrices, may undergo 
significant aging, perhaps resulting to decrease in-vivo performance. 
( 
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C. Effect of aging on the disintegration and dissolution of coated tablets 
As alluded to in the Introduction Section, the major limitation of 
sugars as direct compression vehicles, is the high hygroscopicity. Often 
time, a formulator may circumvent this problem by coating the tablets . 
Although coating processes such as the application of enteric coating to 
tablets have been used in industry for a long time, little consideration 
has been given to the adaptability of such coating to tropical- like con-
ditions. 
A study was designed to evaluate the effect of moder ate stress con-
ditions on the disintegration and dissolution of several coated tablet 
products (commercially available). Tables XXIII through XXVI show the 
disintegration of the tablets studied, before and after aging. A com-
parison of the dissolution data, evaluated by two methods, i . e . dissolution 
efficiency approach, and absorbance at various t"dime points, is shown in 
Tables .X.XVII through .XXX for prednisone (plain, film coated chlorproma-
zine, sugar coated chlorpromazine, and enteric coated aspirin respectively. 
Figures 49 through 52 are dissolution profiles of the four products studies. 
It is common when designing quality control dissolution specifications, 
to use one point type tests. For example, "n.ot less than eighty percent 
of the label claim shall be dissolved in thirty minutes". Although such 
specifications can be of value for the purpose of batch to batch variation, 
they are nevertheless limited when investigating dissolution in detail, 
such as is required in preformulation studies or in investigating tablet 
aging. Therefore there is considerable advantage in obtaining data which 
define the entire dissolution curve. The dissolution pattern of sugar 
coated chlorpromaziae in this study exemplifies the need for dissolution 
data to describe the entire dissolution process (Figure 51). If this had 
) 
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TABLE XXIII 
Effect of Storage on the Disintegration Time 
of Prednisone 
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Week * Storage condition Disintegration time (range) 
(Min) 
* 
0 
2 
2 
4 
4 
4 
A 
B 
c 
D 
E 
B 
c 
D 
E 
1 - 1.5 
A - room temperature, B - 30°C Cyclic, C - 30°c Constant, 
B - 30°C/RH Cyclic, 30°C/RH Constant 
TABLE XXIV 
Effect of Storage on the Disintegration Time 
of Film Coated Chlorpromazine 
129 
Week * Stor age condition Disintegration time (range) 
(Min) 
* 
0 
2 
2 
2 
4 
4 
4 
4 
A 
B 
c 
D 
E 
B 
c 
D 
E 
5 - 8 
5 - 13 
6 - 14+ 
5 - 8 
5 - 14+ 
5 -
5 - 11 
5 - 11 
5 - 11 
A - room temperature, B - 30°C Cyclic, C - 30°c Constant , 
B - 30°C/RH Cyclic, E - 30°C/RH Constant 
+Statistically significant from disintegration time for untreated samples 
) 
) 
TABLE XXV 
Effect of Storage on Disintegration Time 
of Sugar Coated Chlorpromazine 
Week * Storage condition Disintegration time ( r ange) 
(Min) 
* 
0 
2 
2 
2 
4 
4 
4 
4 
A 
B 
c 
D 
E 
B 
c 
D 
E 
15 - 18 
6 - 7+ 
6 - 7+ 
6 - 7+ 
6 - 7+ 
6 - 7+ 
6 - 7+ 
6 - 7+ 
6 - 7+ 
A - room temperature, B - 30°C Cyclic, C - J0°C Constant, 
B - 30° / RH Cyclic, E - 30°C/RH Constant 
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+Statistically significant from disintegration time for untreated samples 
) 
TABLE XXVI 
Effect of Storage on the Disintegration Time 
of Enteric Coated Aspirin 
131 
Week * Storage condition Disintegration time (range) 
(Min) 
* 
+ 
0 A 66 - 68 
2 B 66 - 76 
2 c 66 - 80 
D 64 - 98+ 
2 E 66 - 75 
4 B 65 - 78 
4 c 67 - 70 
4 D 65 
- 70 
4 E 66 - 69 
A - room temperature, B - J0°c Cyclic, C - J0°c Constant, 
B - J0°C/RH Cyclic, E - 30°C/RH Constant 
Statistically signficant from disintegration time for untreated samples 
) 
TABLE .XXVII 
Effect of Storage on the Dissolution 
of Prednisone lOmg Calibrator 
Week * Storage condition 
Prob > t + 
Dissolution efficiency 
* 
+ 
2 B 0.53 
c 0.05 
2 D 0.09 
2 E 0.09 
4 B 0. 74 
4 c 0.41 
4 D 0.15 
4 E 0.62 
B - 30°C Cyclic, C - 3o0 c Constant. D - 30°C/RH Cyclic, 
E - 30°C/RH Constant 
Indicates significance if < 0.05 
132 
Prob> t 
Absorbance 
0 . 64 
0.48 
0.46 
0.57 
0 .98 
0.82 
0.62 
0.92 
) 
TABLE XXVIII 
Effect of Storage on the Dissolution 
of Film Coated Chlorpromazine 
Week * St orage condition 
Prob > t + 
Dissolution efficiency 
* 
B o. 710 
2 c 0.030 
D 0.160 
2 E 0 . 040 
4 B 0.060 
4 c 0 . 570 
4 D 0.110 
4 E 0.500 
B - 30° Cyclic, C - 30°c Constant, D - 30°C/RH Cyclic, 
E - 30°/RH Constant 
+Indicates significance if < 0 . 05 
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Prob > t 
Absorbance 
0.87 
0 . 61 
0 . 52 
0.49 
0.88 
0.34 
0.99 
0 . 23 
) ) 
) 
TABLE XXIX 
Effect of Storage on the Dissolution 
Sugar Coated Chlorpromazine 
* Prob > t 
Week * Storage Condition Dissolution efficiency 
* 
2 
4 
4 
4 
4 
B 0 . 0300 
c 0.0030 
D 0.0020 
E 0.1900 
B 0.0800 
c 0.0030 
D 0.0003 
E 0.0010 
B - 30° C Cyclic, C - 30°c Constant, D - 30°c/RH Cyclic, 
E - 30° / RH Constant 
+Indicates significance if < 0.05 
Prob > t 
Absorbance 
0.9900 
0.0300 
0.6300 
0.9900 
0.1300 
0.0010 
0.0003 
0.0010 
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) 
TABLE XXX 
Effect of Storage on the Dissolution of Enteric Coated Aspirin 
Week 
2 
2 . 
4 
4 
4 
4 
* Storage condition 
B 
c 
D 
E 
B 
c 
D 
E 
Prob > t + 
Dissolution efficiency 
0.001 
0 . 034 
0.480 
0 . 094 
0.460 
0.001 
0.390 
0.350 
*B - 30°c Cyclic, C - 30°c Constant, D - 30°/RH Cyclic, 
E - 30°C/Rll Constant 
+ 
Indicates significance if < 0. 05 
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Prob > t 
Absorbance 
0.320 
0.0002 
0.230 
0.470 
0.400 
0 . 029 
0 . 750 
0.230 
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been restricted to the determination of the percent of drug dissolved 
at sixty minutes, the conclusion would have been reached that no signif-
icant change in dissolution had occurred. However, even simple visual 
inspection of the entire dissolution curve clearly indicates that storage 
under stress conditions alters the dissolution pattern of sugar coated 
chlorpromazine. 
In comparing the dissolution profiles for the four products (before 
and after exposure to the various stress conditions), two methods were 
used . Firstly, the mean dissolution efficiency (six replicates), as de-
fined by Khan and Rhodes (12 ) was determined, and the change in this para-
meter evaluated statistically using Student ' s t - test. Although this 
approach offers a convenient method whereby the entire dissolution profiles 
can be evaluated, "dissolution efficiency" is a derived value, rather 
than a raw experimental datum . Therefore, a second method of evaluating 
dissolution data was used. The second method involved a direct compari-
son of the percent d~ug dissolved at specific time points using Student's 
t-test (128). 
Both disintegration and dissolution data (Table XXIII and Figure 
49) for prednisone showed no significant change. The dissolution profiles 
(before and after exposure)were virtually superimpossible. This finding 
suggests that the product is reliable as a dissolution standard. 
Results for the film coated chlorpromazine did not indicate any sig-
nificant change in disintegration and dissolution characteristics. Although 
the Student's t-test using dissolution efficiency showed a significant 
change in dissolution for samples stored under 30°c constant, and 30°C/RH 
constant for two weeks, this difference was not detected when raw data 
were compared. 
) 
) 
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Both the disintegration and dissolution <lata for sugar coated 
chlorpromazine (Table .XXV and Figure 51) showed significant changes as 
a result of storage. Examining the dissolution profile of this product, 
it appears that the aging changes are probably associated with the sugar 
coating rather than the tablet core . 
The results of the evaluation of the enteric coated aspirin (Table 
XXX and Figure 52) showed that the product was susceptable to significant 
aging. The dissolution of this product is extremely slow even for non-
stressed samples. Although the only really conclusive proof that a bio-
availability problem exists with enteric coated aspirin would be data 
from an in-vivo blood level study, these data suggest that enteric 
coated aspirin has potential for aging problems . 
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CONCLUSIONS 
The following are believed to be the major points of this work as 
reported and discussed in the previous section. 
The new sugar matrices produced by California and Hawaiian Sugar 
Company (C & H) sh""' considerable potential as direct compression vehicles. 
In particular, C & H B exhibits the t ype of flow and compressibility that 
are essential for high speed tablet production . 
Currently, the use of sugar matrices is mainly in the formulation of 
chewable tablets. However, as demonstrated in this study, if a direct 
compression matrix has the adequate flow and compressibility, its use can 
include the formulation of conventional tablets. Although there is in-
creasing concern in some parts of the world, such as in the United States, 
on the role of sugar in dental decay, the level that is incorporated into 
a single tablet, for example of 250 mg , is of very little significance; 
most especially if the tablet is swallowed. Nevertheless. sugar matrices 
should be used judicially as they may pose a significant problem to diabetics 
in case where they may take a given formulation repeatedly. At present9 
sugar is experiencing severe price depression on the world market. This 
has resulted from a combination of high production and a decline in the 
use of the product as a sweetener. Many of the sugar producing countries 
are developing nations. It is thus believed that if the utility of the 
product was to be expanded (although the pharmaceutical industry would not 
consume as much tonnage as the beverage industry) this would be an added 
economic benefit to the producing countries. Faced with foreign currency 
shortage, partially as a result of high petroleum prices, many developing 
countries have imposed severe import restrictions. Although in most of 
) 
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these nations such restrictions have not yet included the very much needed 
pharmaceuticals, it is conceivable that as world prices of petroleum and 
other finished goods keep rising, a significant number of these countries 
may be forced to restrict the importation of pharmaceutical products. 
One of the solutions to the import problem is to develop a sound domestic 
program where locally available resources can be fully exploited. The 
expansion of the use of sugar, particularly in its modified form (suit-
able for tablet manufacture) is an example of such an effort. 
This study demonstrates the importance of raw material specification. 
When two batches of C & H A (differing only in their particle size dis-
tribution spectra) were evaluated, significant differences were observed, 
both in their intrinsic properties and in their tableting characteristics. 
Such differences are particularly critical in the production of tablets 
by direct compression, since little or no change in the material is af-
fected before incorporation into a formulation mixture. However, in wet 
granulation, through the various steps involved in the process, many in-
herent ingredient deficiencies may be corrected . The organizations or 
agencies, such as the United States Pharmacopeal Convention, that are 
charged with the responsibility of establishing standards for both law 
materials and finished products (in the pharmaceutical industry) are be-
coming increasingly aware of the fact that raw material . in different forms, 
may differ significantly in performance. Such awareness is exemplified 
in the compendial monographs for some disintegrants. Here. submonographs 
have been established to reflect the properties of various forms of the 
raw materials . The data obtained in this study shows the relevance of such 
specifications. Further, the study shows that a systematic approach can 
be used to monitor the entire tablet formulation process with relatively 
) 
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little instrumentation. 
Investigation concerning the stability of pharmaceutical products 
encompass fundamental studies on the rates and mechanisms of the reac-
tions of the active ingredient(s), and the determination of the role of 
the container, the effect of storage and distribution of the finished 
production on the integrity of the formulation. A standard approach 
towards stability evaluation has never been attained in the pharmaceutical 
industry. Although the stability of most heterogeneous dosage forms can 
be monitored relatively easily, solid dosage forms, particularly tablets, 
present a difficult task. Many researchers in the industry employ high 
temperature and humidity (usually in a constant mode) in an attempt to 
predict the stability of drug product at room conditions. A great number 
of the stress conditions currently used do not reflect neither climatic con-
ditions of any region of the world nor actual storage conditions that 
a drug product could be exposed to . A commonly overlooked fact is that 
in no geographical region of the world do constant temperature and humidity 
prevail. The more natural situation, even in the tropics, is one in 
which temperature .and humidity may be high during the day, but drop con-
siderably during night time, i.e., cyclic change. This study compares 
the effect of both constant and cyclic changes on the stability of tablet 
formulations, and shows that cyclic storage conditions may indeed be more 
stressful than constant storage conditions for some formulations. 
The results reported in this thesis clearly demonstrate the potential 
commercial utility of at least one of the C & H Sugars. Further, it is 
felt that this study helps to substantiate the belief that a rational, 
logical, largely objective series of tests can be successfully used to 
evaluate most, if not all, aspects of tablet matrix evaluation. 
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[57] ABSTRACT 
A crys1alli zed sugar producl contai ning a heat-sensi-
tive, acidic, o r high invert sug:ir suhs1ance is prepa red 
by admi xing 1he heat-sensitive, acid ic, o r hig h inve rt 
suga r substance with a dry suga r base to form a premix, 
concen trating a suga r syrup containing at least about 
85% by weight sucrose to a solids conten t of abou t 95% 
to aboul 98% by heating 10 a tempc:rature of about 255• 
F . to abo ut Joo• F., mi xi ng the p remix wilh the concen-
trated sugar sy rup to fo rm a mix1ure, "ubjec ti ng the 
mixture 10 impact be:uing wi1hin a crystallization zone 
until a d ry c rystallized suga r product is formed, and 
recovering the sugar produc t fro m !he cryst:1 lli za1io n 
zone. The resulting sugar product compri~cs aggrega1es 
of fon dant-size sucrose crysla ls inlimately assoc ia led 
with the he3t-sensitive, acid ic, o r high invert sugar 
substance. The sugar product is d ry, gran ular, free-
fl o wing, non-caking, and readily dispersible in water. 
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2 
CRYSTALLIZED, READILY WATER 
DISPERSIDLE SUGAR PRODUCT CO:-ITAINING 
HEAT SENSITIVE, ACIDIC OR lllGH INVERT 
SUGAR SUBSTANCES 
SUMMARY OF THE INVENTIO N 
By mcan!i or the prc!.Cnt inventio n, a crys1a lli zed 
sugar producl is produced whic h incorporates a heat-
s sensitive, acidic, o r high invert sugar subslance. The 
product is d ry, granular, free-flowing. and non-caking. 
BACKGROUND OF THE INVENTION The product is composed of agglomerates o r aggregates 
This invent io n rclate5 10 3 process o f producing 3 or minute, fondan1 -siie sucrose crys1als o r part icles intimately associa1ed wilh the active ingredicnl . Due to 
granula r, free-flowing, non-caking sugar inco rporalcd 10 its porous structure, the cryslallized sugar product is 
product. Mo re !.pcciri1.:ally, this invention relates to a readily dispersed or dissolved in water. 
crySl:dllizcd sugar product which incorpora les a heat- The crysta llized sugar product of the present inven-
scm.i1ive, acidic, or high invert sugar content substance lion is prepared in a two-stage process. In the first stage, 
and 10 a process for making the sugar incorporated a premix is prepared by mixing a dry granular o r lrans-
product. 15 formed sugar base wil h a hcaH•cnsitive, acidic, or high 
In !he manufacture of sugar products, a process inve rt sugar substance. In !he second o r cocrysta lliza-
known as 1he tr:rnsformi~g process is. used 10 rroducc a tion stage, the crystallized sugar product is prepared by 
dry.' gr~nula r •. fre~-.nowmg: no n-caking . sugar prod~ct concentrating a sugar syrup 10 about 95-98% by weigh t 
whic h 1s readily d1spcr~ed 1~ wale r. This transfo rming solids by heating at a lemperature in the range from 
pr~ess has been de~nbed m. U.S. Pat. Nos. 3,149,682 20 about i55"-30Ct F ., mixing the concentrated sugar 
(Tippens ct al.), 3,~65,331 (Miller et al.), and 4,159,~JO sy rup with a predetermined amoun t of the premix, sub-
(Chen el a~.). In Tippens et al.. the method comp~ises jecting the new mixture ro impact healing withi n a 
co1~ccnt ra11ng_ a sugar sy rup 10 about 95-97% by "'.eight crysta lli zation zo ne until a crysta lli zed sugar product 
!>ollds by heat mg the sugar syrup to a temperature 1n the made u o f aggregates o f fondant-!>ize sucrose crysta ls ~ange of abou_t 250"-2b5" F., and immedia1ely subject- zs and th/heat-sensitive, acid ic, o r high invert sugar sub-
1~g .the . resuh1ng ~upe~salurated sugar . syrup to a he~t stance is formed, lhe crys1allizt!d sugar producl having 
d1ss1pa11on opcralJOn s1mul1aneously with vigorous ag1- a moisture conlen t of less than 2.5% by weight, and 
lat.ic:>"· The method produces a ~ry sugar pr~uct com- recovering the crystallized sugar product from the crys-
prismg aggregat~ of fondant-s~ze (3-.50. microns) s~ - tallization zone. If desired, the resulting crystallized 
cro~ c~ystals. M11l~r el _al. describes a s1m1.lar process m JO sugar product may be dried to a moisture content ofless 
wh ich impact beat mg 1s used 10 crystallize the sugar than I% by weight, followed by screening to a uniform 
produc1 from lhe supersaturated sugar syrup. size and packaging. 
The feed syrup which is used in the processes of 
Tippens et al. and Milh:r ct al. has a purity in the range DETAILED DESCRIPTION OF THE 
of 85-97% by weight sucrose. Thus, invert sugar (equal 35 INVENTIO N 
portions of g lucose and fruclose), which has a tendency The accompanying drawing is a now chart illustrat-
to cake, may not comprise more than about 15% by ing a preferred process or scheme for preparing a crys· 
weight of the feed sugar syrup. tallized sugar product in accordance wi1h 1he presen t 
The 1:; ugar products prepared in accordance with the invention. 
processes of Tippens ct al. and Miller ct al. arc usefu l as 40 Referring 10 the now chart, the process oft he present 
ca rriers for food additives, such as colorants, navoran ls, invention comprises two stages. In the first stage, a 
and pharmaceuticals. The food additives may be intro- premix containing an active ingredient is prepared. The 
duced into the suga r sy rup al either the concen tration active ingredic:nt 10 in a dry srnle is blended wi th a dry 
o r the crystalliz.ation stage of the processes, depending sugar base 12 such as a granular or transformed sugar, 
o n the nature of the additive. However, the high tern· 45 to form a dry premix 14. The ac1ive ingredient com-
pe ratures used in the transforming process (about prises a heat sensitive, acidic, or high invert suga r sub-
250•- 265• F.) restrict the nature of the food addit ives stance. For example, the active ingredient may be a heat 
which may be incorporated into 1he final sugar product. sensitive substance, such as a volatile navor or an cn-
Heat-sensitive ingredients, such as volatile navors o r zyme, or an acidic substance, such as Vitamin C (ascor-
enzymes. cannot be incorporn1cd in10 the sugar product 50 bic acid) o r a fruit juice concentrare, or a high invert 
by the methods described . Further, acidic ingredients, sugar substance, !>uch as honey or molasses. The dry 
such as Vitamin C o r fruit juices, ch:rnge sucrose into sugar base may be pure suc rose or may contain up to 
invert sugar by the reaction known as suga r inversion. about 15% by weight of non-sucrose so lids comprising 
A further restriction in these processes is that the feed addiiional monosaccharides, disaccharides, o r modified 
syrup must conta in less than 15% by weigh t invert 55 dextrins. For e:tamplc, the non-sucrose solids may com-
sugar. prise invert sugar, dextrose, fructose, corn sy rup, malto-
Accordingly. it is an object of this inve ntion to pro- dcxtrins, or mixtures thereof. The amoun l and type of 
vide a sugar product which incorporates an edib le heat- sugar base which is used may va ry depending upon the 
sensi tive, acidic, or high invert sugar substance. amount and nature of the :ictive ingredient. llle active 
It is also an objec1 of this invention to provide this 60 ingredient is blended with lhe sugar base, fo r e>.amplc, 
sugar product in granular, free-nowing, noncaking by means of a Hobart Olendcr, unti l the desired degree 
form. of homogeneity of the premix is achieved. 
It is also an object 10 provide this sugar product in a In the second stage o f the operation, cocrys1allization 
form which is readily dispersed o r di!>solved in water. of sugar wi th the active ingredient is achieved. A sugar 
It is a further object of this invenlion 10 provide a 65 sy rup 20 containi ng at leas! 85% sucrose is concen-
mcthod of preparing this sug:ir product. trated by evaporation 22, under vacuum or under almo· 
These and o ther objects arc accomplished by means spheric pressure, at a temperature in the range of :lbout 
of 1he present invention dt"scribed below. 255°-Joo· F ., depending upon the nalure o f the aclive 
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material, until the solids content of the concenlra ted dc1crioration of the active ingredient by !he high tem-
sugar syrup exceeds about 95%. The non-sucrose so lids pcra1ure. The premix become!. thoroughly mixed in the 
) in the feed syrup may comprise additional monosaccha- earlier stages of the crystallization step as the concen-rides, di!.accharides, or modified dextrins, for example, trated sy rup is transformed from the liquid slate 10 a 
invert sugar, dextrose, fructose, corn sy rup, maltodex- 5 semi-so lid state. Consequently, when the syrup reaches 
trins, or mixtures thereof. the relatively dry agglomerated stale, the resulting 
The resulting supersaturated suga r syrup 24 having a product is a homogeneous blend of 1he cocrystallized 
solids con1e n1 exceeding abou1 95% by weighr is main· sugar ;ind ac1ive ingredient. 
tained at a 1empcra1ure not less than aboul 240· F . in The phy'iical structure of the crystallized sugar prod-
order to prevent pri:mature cryslallizat io n. A predetcr· JO uct is highly dl!pendent o n the raie and tcmpera1ure o f 
mined amoun t of the premix prepared in the first stage impac1 bea1ing and crys1a ll ization, and on the deg ree o f 
o f 1he proce~s is added 26 to the conccnlrated syrup suga r transformation . The optimum time for the con· 
with vigorous mechanical agitalion or impac1 beating ccntraled sy rup mix1ure to spend in the crys1allit.ation 
28 wi1hin a suitable crystalliza1ion zo ne , such as a J{o. zone during impacl beating depends o n seve ral factors 
hart Mixer or Turbuli ze r. Alternatively, the concen- IS including: (a) the na1ure of the non-sut.:rose solids (such 
tra1ed syrup may be added to a predetermined amount as invert sugar and ao;h) in the syrup; (b) the nature and 
of lhe premix and mixed in a similar manner. c haracteristics of the active ingredien t (such as moisture 
Impact beating is continued until the resulting super· conten t, invert sugar content p H, etc.); (c) the concen· 
saturated syrup is transformed, crystallized 30, and ag· !ration of the active ingredient in the premix: and (d) the 
glomcrnted 32. A crystalline sugar incorporated prod· 20 temperature used for concentration of 1he feed S)' rup. 
uct 34 is recovered from the crysta lli zat io n zone. The Jn structu re, the crys1a ll ized ~ugar products of the 
latent hc:at of crystalliza tio n is sufficient to evaporate present invention is comprised ofaggrega1es or agglom-
1he moislure so that the product is substantially dry, i.e., cra tes of fond:lnt-l:iize sucrose crystals, e.g., in !he range 
has a moisture content o f less than about 2.5%. If de· o f about 3-SO microns, intimaidy associated with the 
si red, the crystalli zed sugar product 34 may be further 2S non-sucrose solids. The agglomerates form a loose. 
dried to a moisture content of less than I%, followed by lacey network bonded together at their in terfaces by 
screening and packaging 36. point con tact. Accordingly, aqueous liquid can rapidly 
During crystalliz.at ion, it is desirable 10 remove the pcne1ra1e the porous cluster of agglomcr31C:S and free 
heat of crys1allization to prevent overheating within the each of the particles making up the agglomerates. The 
c rystall ization zone. The heat of crystallizat io n can be JO particles thus become readily dispersed and/or dis· 
removc:d o r dissipated by indirect heat exchange e.g., by so lved in the aqueous liquid. 
surrounding the crystallizat ion zone with a water In 1he crystallized suga r product oft he present inven· 
jacke1, o r, preferably, by forced air now through the tion, the active ing redient is incorpor;;it ed as an in1egral 
) healer-crystallizer, e.g., with 3 va po r separator. part o f the sugar matrix and !here is no tendency for the Suitable apparat us for car rying o ut the process of the JS active ingredien t 10 separate o r se ll le ou t during han· present invention is described in U.S. Pat. No. 3,365,331 dling, packaging, or storage. The resuhing product is 
(Miller et al.). granula r, free-newing, non-caking, and is readily dis· 
In o rder to ensu re maximum homogeneity in the final persed o r dissolved in water. Data from a typical analy-
product, it is desirable to introduce the premix into the sis of three different sugar incorpora1ed products pre· 
concent rated syrup as early in the process as practical. 40 pared in accordance with the present invention are 
However, in most cases, the premix is introduced dur· presented in Table I. 
ing the suga r crystallization step in order to prevent 
TABLE I 
Honey F11vorcd Sugar lncorpor11ccl Sug:u lm.:orpora1ed 
Sugar Jnveruasc Produc1 Grarc Juu::c Producl 
Firs1-S1age O~ration; 
(Prem~ Preparation) 
Compasi1ion Honey/ Sugar Liquid Grape Ju ice 
lnvcrll~Sugar Cnnccnlr:ue 
(68" Bm)!Sugar 
(Wt. R11io) (I/I) (119) on> 
Second-Stage O~ration : 
Composi1ion Prcmi ... /Sugar Prcmi,.,/Sugar Premi ... /Sugu 
(WI. R11io) (2/)) (I/I) (I/I) 
Elcv11cd Temperature 28!1° F. 270' F . 290· F. 
Solids Con1cn1 Of 
Supcrsa1ura1cd 
Solution 91. J 97.0 
'" (W1. %) 
Finished Producl Anatxs•s 
Sucr())C(Wt.%) 79.S 9U 88.6S 
Inver! Sugar 
Conlen1(W1. 'l"o) 17.2 O. ll 912 
Moisiure Con1cnl (Wt. %) 0.7S 0.45 0.6S 
Screen An1lysi5 (%) 
No. 21 21.S 11.2 25.8 
No. JS 21.7 17.0 24.5 
No. 48 25.6 20.S 20> 
No. 65 12.S 17.1 17.6 
No. 100 .. 12.4 
'-' No. 200 '-' 10.0 1.6 
) 
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TABLE I-continued 
Honey F11vorc:d Sugar lncorpor1rcd Sugar ln~·orpor11cd 
Sugar lnvc:rll~ Product Grape Juice Produc1 
P•o 0.6 4.1 0., 
A wide va riety of producls may be made in acco r-
dance wi1h the present invention. The following exam-
ples illust rate some embodimenls of this invention bUl 
are not meant in any way to limit the scope 1hereof. 
A navored sugar product may be prepared by incor-
porating a Oavorant into a crystalline sugar matrix. The 
navorants include vo)a lil e navors, such as acct.a ldehyde 
or diacctal, nonvolatile navors, such as natural navor 
sugar solution at 65• Brix was heated 10 285• F. 10 form 
a ~upersa1urated sy rup of approximately 98% solids 
con1ent. The supersaluraled sugar solution was added 
10 10 1he premix with impact beating. Impact beating was 
continued and crystallization proceeded unlil a dry 
powdered product was formed. 
EXAMPLE 6 
e"tracts or artificia l flavorings, and essen tial oils, such IS 150 grams of grape juice concentrate (68" Brix) was 
as lemon oi l or peppermint oil. The product made in this mixed wi1h 350 grams of sugar (Bakers Specia l Grade) 
manner provides a fast flavor-releasing character due to to form a slurry . The process continued as in Example 
the c rystalline sugar matrix . 5. The grape juice incorporaled producl ca n be used in 
EXAMPLE I a grape jelly mix formulation by dry blending wi1h IO. 7 20 grams of pectin. 
100 g rams of natural peppermint oil in a dry slate was ln another embodimen t, a vitamin, such as oxidative 
blended with 300 grams of granu lar sugar (Bakers Spe- vitamin A,C,D,E, o r K, is incorporated into a sugar 
cia l Grade) using a Hobart Blender. At 1he same time, matrix. The resulting product is a homogeneous mixture 
700 grams of a 65• Brix sugar solution wa~ concentra ted with high stabi lity . It can be used to fortify other foods. 
a1 260· F. to 95% by weight solids conten1. 300 grams of 25 
the peppermi nt oil-sugar premix was added to the su- EXAMPLE 7 
persa1urated, hot syrup with mechanical agi1a1ion by an JO grams of Vitamin A pa lmita1e (Type 250-SD Hoff-
impact beater. Impact bea1ing conlinued until crys1a ll i- mann-LaRoche) was admixed wi1h 390 grams of trans-
z.ation occurred and a dry sugar product incorporating formed sugar (Di-Pac@) to form a premix. 6CX) grams 
the peppermint oil was produced. JO of a heated, ~upersalurated sugar syrup. prepared as in 
EXAMPLE 2 Example I. was added to the premix wi th mechanical 
agitation. Stirring was continued until the sugar was 
A map le flavored sugar prod uct was prepared ac- transformed and agglomerated into a dry sugar product. 
cording 10 the process described in Example 1. 100 One g ram of this incorporated product providesexac1ly 
grams of artificial maple fl avor (contain ing 2.5% maple JS 2,500 1.U. of Vitamin A. 
flavor, FMC6829) was dry-b ll!nded wi1h 300 grams of In ano1her embodiment, a c hemical having beneficial 
granular sugar (Bakers Special Grade). 300 grams of the properties, such as ferrous sulfate, dicalcium phosphate, 
premix was added to the hot, supersa1 ura1ed syrup with sodium bicarbonate, or a trace mine ral is incorporated 
impact healing until a dry product was formed. into a sugar matrix. The product is a homogeneous 
In anot her embodiment, a high inve rt sugar sub- 40 mixture of the ingredients and can be used 10 fon ify 
slance, such as honey or molasses, is incorporated into a other foods. 
crystalline sugar matrix . The product made in this man-
ner possi:sscs free-flowing and non-caki ng properties 
while retaining a natural delicate fla vor. 
EXAMPLE 3 
EXAMPLE 8 
2.08 grams of stannous nuoride was mixed with 
4S 297.92 g rams of iransfo rmed sugar (Di-Pac@) to form 
a premix. 600 grams of a healed supersa1ura1ed sugar 
200 grams of transformed sugar (Di-Pac@) was syrup, prepared as in Example I, was added to 1he pre-
blcnded wi1h 200 grams of pure honey to form a slurry . mix with impact beating. Impact beating was con tinued 
600 grams of a supersa1urated sugar syrup, prepared in and crystalliza1ion proceeded. eventually resulting in 
Example t. was 1hen added to rhe premix with agita- SO rhe formation ofa dry powdered product. Jn spi1e of the 
rion. Stirring was conlinucd un1il 1he mixture was trans- high chemical activity and acidi ty of 1he fluoride, this 
formed into a dry sugar product. The producl possesses c hemical was successfully incorporated inlo the sugar 
free-flowing charac1eristics and has a delicate honey matrix and the resulting product provides exact ly 1,()(X) 
taste. ppm/gram of !he flu oride. 
EXAMPLE 4 '' EXAMPLE 9 
A product was prepared as in Example 3 using molas- Example 8 was repeated except that JOO grams of 
ses instend of honey. ferrous sulfate was blended with 300 grams of sugar to 
In another embodiment, a dehydrated fruit juice form 1he premix. Sugar inversion by the sulfate was 
product is prepared by incorporating a fruit juice con- 60 avoided due 10 the present process. The homogeneous 
centra1e into a c ryslalline sugar matrix. The resulting iron product can be used to forti fy other foods. 
product is a free-flowing, nonperishable dry powder Jn another embodiment, a dry enzyme product o r an 
which can be used in dry blending formulations. ac1ive culture is produced by incorporating an enzyme, 
EXAMPLE 5 such as invertasc, ce llulose, glucose, isomerase, amy-6S la~e. catalase, glucose oxidase, lac1ase, o r pectinasc, o r 
100 grams of nalu ral apple juice concentrate an active culture, in10 a sugar matrix. Notwi1hstanding 
(65.Brix) was admixed with 400 grams of granular sugar 1he high 1empcrature of the process, the enz.ymc rc-
(Bakers Special Grade) to form a slurry. 777 grams of mains in its active form. 
) 
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EXAMPLE 10 
50 gram-. o f purified invcrrase in liquid form (Conver-
8 
Special Grade) to form a premix. 800 grams o f a healed, 
supersatu rated sugar syrup, prepared as in Example I, 
was added to the premix wilh impact heating. Impact 
bc:uing was continued and crys talli1.ation proceeded, t it@, Wallerstein C ompany) wa3 mixed with 450 grams 
of transformed suga r (Di-Pac@) to form the premix. 
600 grams of a hot supersaturated sugar sy rup, prepa red 
as in Example I. was added 10 1he premix wi th mechani-
S eventua ll y resuhing in the formation o f a dry powdtrcd 
product. 
ca l agi1a tio n. The agita tion was continued until the 
o; ugar was transformed, crysta lli zed and agglomera ted . 
The incorporated prod uct ( 10 grams) was evaluated 10 
wit h re3pect 10 its inverting capabilities by blending 
wi th various concentrations of liquid sugar {10- 40 
grams per 100 mis.) and incubated at 30• C. and 55" C. 
for 1. 5 hours. In spite of the hig h temperature used in 
the process, the experimen tal rcsu hs indica te tha t a IS 
significant po rtio n of the invc=rtase remained act ive. 
In anolhcr embodimen t, a nalura l coloran t, !<ouc h as 
annatto extracts, bee t juice concentrates, bcta-caro1ene, 
grnpc skin extracts, o leo resin paprika, or tumeric ex-
trac1s, is incorporated inlo a suga r matrix. The incorpo- 20 
ralcd product is a homogeneo us, s1able, dry powder 
w hich shows no loss of color s1reng1h or hue and whic h 
can be used in dry blend formulalions. 
EXAMPLE II 25 
100 grams of tumeric color (PT 8-S, Hansen Labora-
1ory) was blended w ith 400 grams o f granular suga r 
(Bake rs Special Grade) to form a p rem ix. 500 grams of 
hea led, supersatura1ed sugar solution, prepared as in 
Example 1, was added to the premix with vigorous JO 
agi tation. The agitation was con1 inucd until all the 
sugar was cryii1a lli zed. The incorporated product was 
eva luated for color hue and for color strc:ngth (Bexin 
con tent). Resu lts showed no signi fii.;an t change in both 
c haracleristics despite exposure to lhe high lemperature JS 
cocrys1allizu1ion process. 
Jn anot her embodiment , an acidu lcnt substance, suc h 
as malic acid , fumaric ac id , adipic acid, tartaric acid , 
cit ric acid, and sodium citrate, is incorporated into a 
suga r matrix . The resulting prod uct is a free-nowing 40 
homogeneous powder w hich can be used in dry blend 
formulations. 
EXAMPLE 14 
The incorporatio n mclhod was 1he ~ame as that used 
in Example 3, using a monoglyccride (Myvcrol 18-07, 
Kodak) ins1ead of Jecil hin. 
In spi te o f 1hc high kmpcratu rc employed in the 
presen t process, the resulting products are frcc-Oowing, 
non-caking, dry, homogeneous, stable, non-perishable, 
and are read il y d ispe rsed o r disso lved in wa ter. 
While the invention has been dco;cribcd wit h re fer-
ence to speci fic embodimenls, these were for the pu r-
poses o f illustralion only and should nol be construc1ed 
to limit 1he scope o f the present invention. 
We clai m: 
1. A method for prepa ri ng a cocrystall ized sugar 
produc1 containing an active ingredienl ~elected from 
the group consisting of heat-sensitive, acidic, and high 
invert sugar substances, comprising: 
(a) admixing the active ingredient with a d ry sugar 
base to fo rm a premix; 
(b) concentrating a sugar syrup al a temperature in 
the range o f abou t 255• F. to abou t 3C~Y F . to a 
solids con lent o f abo ut 95% to 98% by weight, said 
sugar syrup con t:iining no more than abou t 15% by 
weigh t non-sucrose so lids; 
{c) d irectly admixing the concen 1rated sugar syrup at 
a lemperature 255• -300• F. wi th suid premix to 
fo rm a mixlure; 
(d) subjecting sa id resul ting mixture upon admixing 
said premix to impact beating wi thin a cryst<illiza-
tion z.one until a crys1allized sugar product is 
formed, sa id c rystallized sugar product made up of 
aggregates of fondant-siz.e sucrose crystals and the 
active ingredient and having a moisture conten t of 
less tha n about 2.5% by weight ; and 
(e) recovering sa id c rystallized sugar product from 
sa id c rys1alliza1ion zone. 
EXAMPLE 12 2. The method of claim 1 fu rlher comprising drying 
The process of Example 11 was repeated using cit ric 4S said crystallized sugar p roduct to a mois1ure con tent of 
acid instead of tumeric coloran t. less than about I% by weight. 
In another embodiment, an emulsifier, such as leci- 3. A c rystalli zed sugar product made in accordance 
thin, mono- and dig lycericides, propylene glyco l esters, with the method of claim 1. 
sorbi1an esters, polysorbate eslers, polyoxycthylene 4. The c rystallized sugar product of claim 3 wherei n 
30rbitan es1ers, o r lac1yla1ed esters. is incorporated into SO !he ac1ive ingredient is a volat ile navor, a nonvolatile 
a sugar matrix . The c rysta ll ized Product permits rapid fl avor. o r an essential oi l. 
dispersion of the emu lsifier in emu lsi fica tio n npp lica- 5. The crysta lli zed sugar product o f c lai m 3 wherei n 
tio ns. The c rys1alli zed product , when added lo cake mix the ac1ive ingredient is honey. 
or icing mix, provides eJ;ce llent emulsion characteris- 6. The crysla ll ized suga r product o f claim 3 wherein 
tics. For e>.ample, ca ke volume. porosity, and appear- SS the :lCtive ingredient is molasses. 
ance; and icing stability and density arc improved wit h 7. The cryslallized sugar produc t o f claim 3 wherein 
the sugar incorporated emulsi fier as compared wit h an the active ingredient is a frui l juice. 
emulsifier added in the conventional manner. 8. The crysta ll ized sugar product o f clai m 7 wherei n 
EXAMPLE 13 
100 grams o f lecithin (Centrophase C, Central Soya) 
was mixed with 200 grams of granular sugar (Bake rs 
60 
. , 
the fruit juice is o range juice. 
9. The c r>•stallized sugar product o f claim 7 whe rein 
the fruit juice is grape juice. 
..... 
) 
) ) 
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